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Summary 1 
Summary 
Targeting ClpXP protease as anti-cancer strategy 
Cancer is one of the leading causes of death worldwide. The term cancer includes solid 
tumors as well as leukemia which affects parts of the hematopoietic system. Leukemic 
diseases are divided in different subtypes depending on the affected branch of the 
hematopoietic system and on whether the disease is in an acute or chronic phase. Despite 
continuous improvement of treatment and quite high survival rates, recurrence and therapy 
resistance are common problems. Hence, new ways of treatment are urgently needed not 
only for leukemia but also for cancer therapy in general.  
The mitochondrion has been studied as a potential target for cancer therapy for years and 
revealed to be a key organelle implicated in tumorigenesis and progression. Besides 
interfering with mitochondrial respiration, redox balance or apoptosis signaling, targeting of 
mitochondrial proteases may be a novel anti-cancer approach. Recently, mitochondrial 
matrix proteases such as ClpXP have been reported as crucial mitoproteases (mitochondrial 
proteases) in various cancer types, such as acute myeloid leukemia, prostate, bladder or 
breast cancer. Hence, interfering with mitochondrial proteostasis (protein homeostasis) is 
considered as a potential cancer therapy option. ClpP, the proteolytic subunit of the ClpXP 
protease has been intensively studied in bacteria in terms of bacterial growth and virulence 
and therefore represents a target for novel antibiotics. In this regard, the group around Prof. 
Dr. Stephan A. Sieber identified a set of compounds by high-throughput screenings. The 
structures target not only the bacterial but also the human ClpXP protease, which is poorly 
investigated up to now. Due to the novelty of human ClpXP targeting, compounds for 
pharmacological inhibition of human ClpXP are still missing. 
Herein, we characterized various compounds in cancer cell lines derived from acute and 
chronic myeloid and lymphoid leukemia. The inhibitor compounds target either the ClpP or 
ClpX subunit or the whole ClpXP protease and were investigated with regard to their impact 
on cell viability, colony formation, and cell death. Thus, we promote ClpXP as a drugable 
target and give first insights in mechanisms of action of novel ClpXP inhibitors as potential 
anti-cancer agents. 
The investigations on the underlying mode of action further focused on mitochondrial 
integrity and energy production. ClpXP inhibition directly impaired mitochondrial function 
as shown by a direct decrease in ATP levels and loss of mitochondrial membrane potential. 
The increased mitochondrial ROS levels concomitant with enhanced carbonylation of 
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proteins reinforced that inhibition of the protease disturbed the mitochondrial proteostasis. 
Moreover, ClpXP inhibition caused cellular stress and enhanced sensitivity of various 
leukemia cell lines towards cytostatic drugs. 
In summary, this thesis presents ClpXP as an attractive drugable target for cancer treatment. 
Further, novel ClpXP inhibitors were introduced and their functional characterization 
reinforced ClpXP inhibition as an anti-leukemic strategy (Figure 0.1). Finally, the 
investigations on mitochondrial integrity, energy metabolism, and stress signaling opened 
up new perspectives for the potential benefit of combination of ClpXP inhibitors with 
established cytostatic drugs.  
Figure 0.1: ClpXP inhibition exhibits anti-leukemic effects by triggering stress and disturbing 
mitochondrial integrity and function. As crucial part of the mitochondrial protein quality control 
network, the mitochondrial matrix protease ClpXP maintains mitochondrial function and 
proteostasis. Inhibition by ClpXP inhibitors leads to a misbalanced mitochondrial proteostasis which 
impairs energy metabolism, causes oxidative and other stress signals, and loss of membrane 
potential. Thus, ClpXP inhibition exhibits anti-leukemic effects. 
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Targeting Cdk5 to fight tumor-initiating cells 
In a second project, the investigations focused on Cyclin-dependent kinase 5 (Cdk5) and its 
role in tumor-initiating cells (TICs). This project was successfully completed and published 
in the British Journal of Cancer in February 2017 (Appendix B, pages 66-81). 
 
Therein, we proposed the atypical Cyclin-dependent kinase 5 as a promising target for cancer 
therapy by introducing a new role of the kinase in TICs. The small subset of TICs exhibits 
high tumorigenicity and chemoresistance and therefore mediates tumor recurrence and 
metastasis. Various mechanisms have been described to contribute to TIC generation such 
as the epithelial-mesenchymal transition (EMT). Besides, enhanced cell survival and escape 
from cell death of TICS are attributed to, e.g., alteration of proteins involved in intrinsic 
apoptosis signaling such as Bcl-2 family members. Thus, TICs represent a central field of 
interest for novel treatment strategies. 
The serine/threonine kinase Cdk5 is crucial in neuronal development, lymphatic vessel 
formation, and tumor angiogenesis. More recently, increasing evidence exists for Cdk5 to 
have a function in cancer, e.g., in the DNA damage response of hepatocellular carcinoma or 
the EMT process in breast cancer. Although studies pointed to a connection between Cdk5 
and TIC generation, the evidence for the kinase playing a role in TICs was missing so far. 
Accordingly, we focused on Cdk5 in the context of tumor initiation. 
We first revealed that Cdk5 protein was increased in several cancer cell lines and in 
mesenchymal compared to epithelial cells. Likewise, a human tissue microarray staining 
underlined the enhanced expression of Cdk5 in breast cancer tissue in comparison to healthy 
breast tissue. Moreover, we elucidated that pharmacological inhibition and silencing of Cdk5 
impaired cell viability, colony formation, and motility of various cancer cell lines, including 
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mesenchymal and epithelial cell lines derived from breast or bladder cancers. Furthermore, 
we carried out sphere formation experiments in which only TICs were allowed to grow in a 
detached environment. Therein, tumorsphere formation was impaired upon Cdk5 inhibition 
by the small molecule roscovitine. Underlining, stable Cdk5 knockdown diminished 
tumorsphere formation, and, vice versa, transient overexpression of the kinase in a non-
cancerous cell line enhanced sphere formation in vitro. Likewise, Cdk5 silencing led to a 
delayed tumor establishment in vivo. 
Furthermore, we revealed an enhanced detachment-induced cell death in TICs accounting 
for the diminished sphere formation. As a potential signaling pathway responsible for Cdk5-
mediated detachment-induced cell death in TICs, we identified the Foxo1-Bim axis as one 
major pathway affected by Cdk5 knockdown. More precisely, we demonstrated the elevated 
levels of the transcription factor Foxo1. This resulted in enhanced transcription and protein 
expression of the pro-apoptotic BH3-only protein Bim probably accounting for the increased 
cell death of TICs (Figure 0.2). 
 
Figure 0.2: Cdk5 inhibition and knockdown induce cell death in TICs via the Foxo1-Bim axis. Cdk5 
affects protein levels of Foxo1. Phosphorylated Foxo1 is degraded in the cytoplasm. Cdk5 inhibition 
and knockdown lead to elevated amounts of Foxo1 protein, which activates Bim transcription. Upon 
detachment, pro-apoptotic Bim is translocated to the mitochondrion and induces cell death in tumor-
initiating cells leading to impaired tumorsphere formation in vitro and a delayed tumor establishment in vivo. 
In summary, we promote Cdk5 as a potential target in cancer, especially in order to address 
tumor-initiating cancer cells. Besides general effects of Cdk5 inhibition and knockdown on 
cell viability, clonogenicity, and motility, we elucidated its impact on detachment-induced 
cell death. Concluding, we revealed the Cdk5-Foxo1-Bim axis as a potential target to fight 
TICs. 
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1 Introduction 
1.1 Cancers of the hematopoietic system and treatment 
Apart from cardiovascular diseases, cancer is among the most common causes of death 
nowadays. Cancers arising from the hematopoietic system include lymphoma, myeloma, and 
various types of leukemia which are ranked as the 11th frequent of all cancer incidences. 
Subdivided into acute and chronic leukemia, the disease can arise from lymphoid (chronic 
lymphocytic and acute lymphoblastic leukemia) or myeloid progenitors (chronic and acute 
myeloid leukemia) (Figure 1.1).1 Consequently, symptoms of the disease include shortness 
of breath and bleedings due to low erythrocyte and platelet counts. Patients also exhibit 
enhanced susceptibility to infections that is caused by the lack of neutrophils and the 
accumulation of non-functional blasts in the bone marrow and blood.2 
 
 
 
 
 
 
 
 
Figure 1.1: The hematopoietic tree. A simplified scheme of the hematopoietic system is shown which divides 
into myeloid and lymphoid branch. Cells of the immune system and blood cells arise by 
differentiation from hematopoietic stem cells. The different leukemia subtypes can affect the 
myeloid or the lymphoid branch.3 
Chronic lymphocytic leukemia (CLL) represents the most common adult leukemia whereas 
young children mostly suffer from acute lymphoblastic leukemia (ALL). Despite overall 
five-year survival rates of about 60 % due to an improved treatment over the last decades, 
relapse after cytostatic therapy is a common concern.1,4,5 Depending on disease subtype, age 
and health of the patient, treatment of acute forms can include high-dose induction therapy, 
consolidation, and maintenance therapy. Therein, combinations of cytostatic drugs are used, 
amongst others, cyclophosphamide, prednisone, daunorubicin, methotrexate, cytarabine, 
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and vincristine.6-10 For subtypes expressing the constitutively active tyrosine kinase Bcr-Abl 
(Philadelphia chromosome positive leukemia), tyrosine kinase inhibitors such as imatinib 
can be combined with multiagent chemotherapy regimens.11,12 Despite chemotherapy, 
allogenic stem cell transplantation is often the only way to cure the disease.13-15 Therefore, 
the development of new treatment strategies besides the established ones is an urgent issue. 
1.2 Targeting mitochondria for cancer therapy 
1.2.1 Targeting cell death machinery, redox balance, and energy 
production 
Mitochondrial dysfunction is linked to ageing as well as to neurodegenerative diseases like 
Parkinson’s and Alzheimer’s disease that are closely linked to cell death.16-18 Hence, the idea 
of exploiting mitochondrial pathways or energy metabolism for cancer therapy arose over 
the last years (Figure 1.2).19-21 Besides energy production and thus supporting cell viability, 
mitochondria are the central organelles of the intrinsic cell death. Mitochondrial apoptosis 
involves pro- and anti-apoptotic Bcl-2 (B cell lymphoma-2) family proteins responsible for 
the integrity of the mitochondrial outer membrane.22 In general, pro-apoptotic members such 
as BAK and BAX are bound to anti-apoptotic proteins, e.g., Bcl-2 or Bcl-xL preventing 
apoptosis induction. Once activated by certain death inducing stimuli such as DNA damage 
BAX and BAK oligomerization renders the mitochondrial outer membrane permeable. This 
results in cytochrome c release from the mitochondrial intermembrane space and further 
activation of a cascade of caspases (cysteinyl-aspartate specific proteases) ending up in 
programmed cell death.23 Loss of pro-apoptotic proteins or increase of anti-apoptotic Bcl-2 
family members were predescribed to be responsible for cancer cells escaping from 
apoptotic cell death and their resistance to chemotherapy.24,25 Consequently, targeting parts 
of the mitochondrial cell death machinery became a promising anti-cancer strategy. 
Moreover, apoptotic profiling which determines the tumor’s reliance on anti-apoptotic Bcl-2 
turned out to be predictive for the response to chemotherapy.26-28 
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Figure 1.2: Diverse possibilities of mitochondrial targeting for cancer therapy. Mitochondria can be 
addressed in several ways. Mitochondrial energy metabolism or metabolic flexibility can be targeted 
by inhibition of parts of the electron transport chain (ETC). Redox homeostasis of the mitochondrion 
can be addressed by interfering with antioxidant pathways. Further, proteins of the apoptosis 
machinery, for example, anti-apoptotic Bcl-2 proteins which can be neutralized by pro-apoptotic 
BH3 mimetics, serve as target for cancer therapy. ATP, adenosine triphosphate; BH3, Bcl-2 
homology domain 3; CytC, cytochrome c; ETC, electron transport chain; Glu, glucose; Pyr, 
pyruvate; ROS, reactive oxygen species. 
Further, the electron transport chain located within the inner mitochondrial membrane is a 
site of reactive oxygen species (ROS) generation as a by-product of mitochondrial 
respiration. ROS function as signaling molecules to activate proliferation and promote cell 
survival at low concentrations.29,30 Moderate amounts of increased ROS cause DNA damage 
and genomic instability and thus drive tumorigenesis, whereas high oxidative stress leads to 
cell death and senescence.31,32 ROS production of fast proliferating cancer cells is often 
elevated compared to non-cancer cells.33 This in turn forces cancer cells to increase 
antioxidant pathways in order to prevent cell death by high amounts of ROS. Therefore, 
interfering with mitochondrial redox regulation and antioxidant pathways is another 
interesting approach.33,34 In vitro and in vivo studies revealed promising results with 
combined inhibition of glutathione and thioredoxin antioxidant pathways in breast cancer 
models.35  
Furthermore, metabolic flexibility is essential for tumorigenesis and progression. Fast 
proliferating tumor cells mostly depend on aerobic glycolysis, known as the Warburg effect. 
This was formerly but erroneously thought to be an exclusive effect of mitochondrial 
defects.36-39 Conversely, distinct tumor subpopulations do not show the glycolytic 
phenotype. A switch from glycolysis to oxidative phosphorylation reliance was observed in 
terms of chemoresistance. Moreover, cancer stem cells of many cancers were found to rely 
on oxidative phosphorylation rather than glycolysis.40-45 Thus, targeting mitochondrial 
metabolism represents an additional strategy to fight resistant subpopulations of cancer cells. 
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1.2.2 Targeting mitochondrial proteostasis 
The mitochondrial DNA (mtDNA) encodes for 13 proteins, such as parts of the ETC, 22 
tRNAs, and two rRNAs. However, the mitochondrial proteome mainly consists of nuclear 
encoded proteins.46,47 Moreover, ROS produced by the ETC located in the inner 
mitochondrial membrane cause mtDNA and protein damage.48 Consequently, a strictly 
regulated protein import, folding, and quality control of newly synthesized proteins, as well 
as degradation of damaged proteins is crucial for proper mitochondrial function.49-52 This 
network includes chaperones and proteases which in turn are divided into several groups 
depending on function and location within the organelle (Figure 1.3). One subgroup, the 
AAA proteases (ATPase associated with diverse cellular activities), is essential for 
mitochondrial protein quality control. The intermembrane AAA protease (iAAA) and the 
matrix AAA protease (mAAA) are both located within the inner mitochondrial membrane, 
whereas the serine proteases Lon and ClpXP are located in the mitochondrial matrix and 
degrade damaged proteins. In addition, mitochondrial proteases were described to participate 
in regulation of signal transduction by processing of regulatory proteins, mitochondrial 
biogenesis, dynamics, stress response, mitophagy, and apoptosis signaling.50 
 
 
 
 
 
 
 
 
 
Figure 1.3: The mitochondrial proteostasis is maintained by an import, processing, and quality control 
network. Import of nuclear encoded proteins is conducted by translocase outer membrane (TOM) 
complex and translocase inner membrane (TIM) complex. Imported or mitochondrial encoded 
proteins are processed and folded by proteases and chaperones such as heat shock protein 60 
(Hsp60). Misfolded, aggregated or oxidized proteins caused by ROSmt can be cleaved by proteases, 
e.g., the matrix serine proteases Lon or ClpXP. Peptides can be further cleaved to amino acids or 
exported directly by ABC transporters and act as signaling molecules. ABC transporter, ATP-
binding cassette transporter; ETC I-V, electron transport chain complex I-V; IM, inner membrane; 
IMS, intermembrane space; mtDNA, mitochondrial DNA; OM, outer membrane; ROS, reactive 
oxygen species; TIM, translocase inner membrane; TOM, translocase outer membrane.50 
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The crucial role of some mitoproteases such as Lon and ClpXP has been described recently 
in the cancer context.53-59 Consequently, targeting parts of the mitochondrial proteases 
network and thereby interfering with mitochondrial proteostasis represents a new approach 
in terms of cancer therapy.60 
1.2.2.1 The ClpXP protease 
The caseinolytic peptidase proteolytic subunit (ClpP) has been studied for years in 
pathogenic bacteria such as Staphylococcus aureus or Mycobacterium tuberculosis because 
it is crucial for their growth and virulence.61-64 Since then, targeting of ClpP has been 
examined using inhibitors as well as acyldepsipeptides (ADEPs) that activate ClpP as an 
antibiotic strategy.65-67 However, human ClpP, the peptidase subunit of the ClpXP protease 
complex (Figure 1.4), is less studied than bacterial ClpP. Mutations in the ClpP gene are 
associated with the Perrault syndrome which is characterized by symptoms like hearing loss, 
ovarian insufficiency in women, and several neurological deficiencies.68,69  
 
Figure 1.4: Structure of ClpXP protease. The nuclear encoded serine protease ClpXP consists of a hexameric 
ClpX chaperone part and a tetradecameric ClpP peptidase subunit and is located in the mitochondrial 
matrix. ClpX recognizes, unfolds, and translocates substrates into the proteolytic compartment in 
ClpP driven by ATP hydrolysis. ClpP cleaves the polypeptide into small peptides.70 
An accumulation of misfolded or damaged proteins in mitochondria has been described to 
trigger an organelle-specific signaling, the mitochondrial unfolded protein response 
(UPRmt).71 This retrograde signaling aims to restore the mitochondrial proteostasis and 
function, inter alia, by enhanced transcription of nuclear encoded mitochondrial chaperones 
and proteases. Amongst them, heat shock protein 60 (Hsp60) and the ClpP itself were 
described to be upregulated to restore mitochondrial proteostasis and thus have a cell 
survival function.71  
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While the UPRmt has been intensively studied in Caenorhabditis elegans during the last 
years, the mammalian UPRmt signaling is less understood (Figure 1.5).72 Former studies 
suggest that ClpXP regulates the UPRmt and therefore acts as a critical protease in human 
disease pathogenesis.73,74 
 
 
 
 
 
 
 
Figure 1.5: The mammalian mitochondrial unfolded protein response. A disturbed mitochondrial 
proteostasis can trigger the UPRmt. ClpP cleaves accumulating misfolded proteins into peptides that 
are released into the cytosol. An activated JNK2 in turn activates c-Jun which drives CHOP 
transcription. CHOP promotes transcription of mitochondrial chaperones and proteases such as 
Hsp60 and ClpP.71,75,76 CHOP, C/EBP homologous protein; JNK2, c-Jun N-terminal kinase 2. 
1.2.2.2 ClpXP inhibitors 
With regard to the increasing evidence of ClpXP’s key role in human cancer, the group of 
Prof. Dr. Stephan A. Sieber (Department of Chemistry, Technical University of Munich, 
Garching) develops and investigates new compounds targeting ClpXP complex. Different 
structures were identified in Staphylococcus aureus ClpXP (SaClpXP) or SaClpP high-
throughput screenings (SaClpP-HTS). Interestingly, some of the identified structures also 
inhibited the human ClpXP complex. The first group represents phenyl ester compounds that 
inhibit ClpP subunit (Figure 1.6).77 
 
 
 
 
 
Figure 1.6: Phenyl ester ClpP subunit inhibitors and their corresponding probes. Structures with activity 
against ClpP peptidase subunit are shown. TG42 and TG53 represent corresponding inhibitor probes 
of AV167 and TG54 and possess an additional alkyne function. 
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The second group consists of compounds with different activity profiles towards the ClpXP 
subunits or the whole protease (Figure 1.7). While 334 targets the ClpX subunit, 319 and 
339 revealed no inhibitory effect on either ClpX or ClpP subunit but activity on ClpXP 
complex. 335 exhibited no activity on human but in fact on the bacterial ClpXP. 
 
 
 
 
 
 
 
 
 
Figure 1.7: Compounds with different activity on ClpXP identified in SaClpXP-HTS. 334 represents an 
inhibitor of ClpX subunit. 319 and 339 are thought to prevent ClpXP complex formation. 335 has 
shown bacterial but not human ClpXP inhibition.  
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1.3 Aim of the thesis 
With respect to former studies that promote ClpXP as promising target for cancer treatment, 
especially for cancers derived from the hematopoietic system, the aim of the thesis was to 
characterize and establish a set of novel ClpXP targeting compounds. We focused on their 
functional effects and the underlying mode of action in various leukemia cell lines, such as 
K562 (CML), Jurkat (T-ALL), CEM (T-ALL), and HL-60 (AML), and in a hepatocellular 
carcinoma cell line (Huh7). 
 
Therefore, cell viability, colony formation, as well as cell death were initially analyzed. To 
underline the effectiveness of ClpXP inhibition in patient-derived xenograft (PDX) leukemia 
cells, cell death was analyzed in various AML and ALL PDX cell samples. Further, the 
analysis of the sensitivity of a hepatocellular carcinoma cell line should reinforce the 
relevance of ClpXP as an addressable target also for other cancer types.  
In terms of elucidation of a general mode of action of ClpXP inhibition in cancer cells, we 
further used the most potent compound, an inhibitor of the ClpX subunit (334), and the Jurkat 
as well as the K562 cell line representatively for lymphoid and myeloid leukemia cells.  
Hence, substrates and signaling pathways affected by ClpXP inhibition such as the 
mitochondrial unfolded protein response were of particular interest. To gain insight into this 
field, we used a quantitative proteomic approach as well as western blotting and quantitative 
real-time PCR. Furthermore, key experiments for analysis of mitochondrial function were 
performed, such as measurement of ATP levels, mitochondrial ROS production, and analysis 
of mitochondrial membrane potential. Moreover, we analyzed mitochondrial morphology 
by confocal and electron microscopy. 
Finally, we investigated the effect of ClpXP inhibition on chemosensitivity of various 
leukemia cell lines by combining the ClpX inhibitor 334 with different cytostatic drugs, such 
as imatinib, etoposide or vincristine. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Compounds 
ClpP inhibitors (AV167, TG42, TG53, and TG54) and ClpXP inhibitor compounds (319, 
334, 335, and 339) were friendly provided by Prof. Dr. Stephan A. Sieber (Department of 
Chemistry, Technical University of Munich, Garching). 
2.1.2 Technical equipment and reagents Table 2.1:  Technical equipment 
Name Producer 
Axiovert 25/200 microscope Zeiss, Jena, Germany 
Canon EOS 450D camera Canon, Poing, Germany 
ChemiDoc Touch Imaging System Bio-Rad Laboratories GmbH, Munich, 
Germany 
Consort Electrophoresis Power Supply 
E835 
Sigma-Aldrich, Taufkirchen, Germany 
FACS CantoII BD Biosciences, Heidelberg, Germany 
Leica-SP8 confocal microscope Leica Microsystems, Wetzlar, Germany 
Megafuge 1.0s centrifuge Heraeus, Hanau, Germany 
Mikro 22R table centrifuge Hettich, Tuttlingen, Germany 
NanoDrop® ND-1000 Spectrophotometer Peqlab Biotechnology GmbH, Erlangen, 
Germany 
Okolab incubation chamber Okolab S.r.l., Pozzuoli, Italy 
OrionII microplate luminometer Titertek Berthold, Pforzheim, Germany 
PowerPac 200 powersupply Bio-Rad Laboratories GmbH, Munich, 
Germany 
Primus 25 advanced thermocycler Peqlab Biotechnology GmbH, Erlangen, 
Germany 
QuantStudio 3 Real-Time PCR System Thermo Fisher Scientific, Waltham, MA, 
USA 
SpectraFluor PlusTM Tecan, Crailsheim, Germany 
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TB1 Thermoblock Biometra, Göttingen, Germany 
Vi-Cell™ XR Beckman Coulter, Krefeld, Germany Table 2.2:  Biochemicals, compounds, dyes, and reagents for cell culture and assay performance 
Reagent Producer 
Antimycin A Sigma-Aldrich, Taufkirchen, Germany 
Bradford ReagentTM Bio-Rad Laboratories GmbH, Munich, 
Germany 
BSA Sigma-Aldrich, Taufkirchen, Germany 
CCCP Sigma-Aldrich, Taufkirchen, Germany 
CellTiter-BlueTM, CellTiter-GloTM Promega, Madison, WI, USA 
Collagen G Biochrom AG, Berlin, Germany 
Complete® mini EDTA free Roche Diagnostics, Penzberg, Germany 
Cytarabine Sigma-Aldrich, Taufkirchen, Germany 
DMEM PAN Biotech, Aidenbach, Germany 
DMSO Sigma-Aldrich, Taufkirchen, Germany 
DTT AppliChem, Darmstadt, Germany 
EDTA Carl Roth, Karlsruhe, Germany 
Etoposide Sigma-Aldrich, Taufkirchen, Germany 
FCS PAA Laboratories, Pasching, Austria 
Ficoll-Paque PLUS GE Healthcare Life Sciences, Freiburg, 
Germany 
FluorSaveTM Reagent Merck, Darmstadt, Germany 
Formaldehyde solution 10 % AppliChem, Darmstadt, Germany 
HBSS buffer Sigma-Aldrich, Taufkirchen, Germany 
High-Capacity cDNA Reverse 
Transcription Kit 
Applied Biosystems, Foster City, CA, 
USA 
H2O2 30 % Merck, Darmstadt, Germany 
Hoechst 33342 Sigma-Aldrich, Taufkirchen, Germany 
Imatinib mesylate Sigma-Aldrich, Taufkirchen, Germany 
IMDM with L-Glutamine Thermo Fisher Scientific, Waltham, MA, 
USA 
JC-1 Enzo Life Sciences, Farmingdale, NY, 
USA 
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Methylcellulose Sigma-Aldrich, Taufkirchen, Germany 
Mercaptoethanol Sigma-Aldrich, Taufkirchen, Germany 
MitoSOXTM Red Thermo Fisher Scientific, Waltham, MA, 
USA 
MTT Promega, Madison, WI, USA 
Non-fat dry milk powder (Blotto) Carl Roth, Karlsruhe, Germany 
Oxidized Protein Western Blot Kit Abcam, Cambridge, UK 
Page-RulerTM Prestained Protein Ladder Fermentas, St. Leon-Rot, Germany 
Penicillin/Streptomycin PAN Biotech, Aidenbach, Germany 
PI Sigma-Aldrich, Taufkirchen, Germany 
PMSF Sigma-Aldrich, Taufkirchen, Germany 
PowerUp TM SYBR Green Master Mix  Applied Biosystems, Foster City, CA, 
USA 
Pyronin Y Sigma-Aldrich, Taufkirchen, Germany 
Pyruvate PAA Laboratories, Pasching, Austria 
Qiagen RNeasy Mini Kit Qiagen GmbH, Hilden, Germany 
Q-VD-OPh Merck, Darmstadt, Germany 
RotiphoreseTM Gel 30 Carl Roth, Karlsruhe, Germany 
RPMI 1640 with L-Glutamine PAN Biotech, Aidenbach, Germany 
SILAC RPMI 1640 w/o L-Glutamine, 
L-Arginine, L-Lysine 
Thermo Fisher Scientific, Waltham, MA, 
USA 
Taqman Master Mix  Life Technologies Corporation, Carlsbad, 
CA, USA 
TCE Sigma-Aldrich, Taufkirchen, Germany 
Tris base, Tris-HCl Sigma-Aldrich, Taufkirchen, Germany 
Triton X-100 Merck, Darmstadt, Germany 
Trypsin PAN Biotech, Aidenbach, Germany 
Tween 20 Bio-Rad Laboratories GmbH, Munich, 
Germany 
Vincristine sulfate Sigma-Aldrich, Taufkirchen, Germany 
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PBS (pH 7.4)  PBS + Ca2+/Mg2+ (pH 7.4) 
NaCl 132.2 mM NaCl 137 mM
Na2PO4 10.4 mM KCl 2.68 mM
KH2PO4 3.2 mM Na2PO4 8.10 mM
H2O KH2PO4 1.47 mM
 MgCl2 0.25 mM
 CaCl2 0.5 mM
 H2O   
   
K562, CCRF/VCR-CEM medium  Jurkat medium 
RPMI 1640 500 ml RPMI 1640 500 ml
FCS 50 ml FCS 50 ml
Pen/Strep*  5 ml Pyruvate 100 mM 5 ml
 Pen/Strep* 5 ml
  
HL-60 medium Huh7/MDA-MB-231 medium 
IMDM 500 ml DMEM 500 ml
FCS 100 ml FCS 50 ml
Pen/Strep* 5 ml Pen/Strep* 5 ml
  
Collagen coating solution Trypsin/EDTA 
Collagen G  0.001 % Trypsin 0.05 %
PBS EDTA 0.20 %
 PBS 
  
*Pen/Strep: Penicillin 10 000 Units/ml, Streptomycin 10 mg/ml 
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2.2 Methods 
2.2.1 Cell culture 
Different cell lines of human lymphoid and myeloid leukemia were used. The chronic 
myeloid leukemia (CML) cell line K562 was purchased from Leibniz Institute DSMZ 
(Braunschweig, Germany). The T-ALL (T-cell acute lymphoblastic leukemia) cell line S-
Jurkat were provided by P. H. Krammer and H. Walczak (Heidelberg, Germany). CCRF-
CEM and vincristine-resistant (VCR-) CEM (T-ALL) were obtained from M. Kavallaris 
(Sydney, Australia) and HL-60 (Acute promyelocytic leukemia) cells were purchased from 
ATCC (Manassas, VA, USA). Huh7 cells were purchased from the Japanese Collection of 
Research Bioresources (JCRB) (Osaka, Japan) and the human mammary carcinoma cell line 
MDA-MB-231 was obtained from Cell Lines Service (Eppelheim, Germany). Cells were 
routinely cultured under constant humidity at 37 °C and 5 % CO2. Cell density was kept 
between 0.1 x 106 and 1 x 106 cells/ml (K562, Jurkat, HL-60) and 0.2 x 106 and 2 x 106 cells/l 
(CCRF-CEM, VCR-CEM). Cell number and viability were determined using Vi-CellTM XR 
cell viability analyzer (Beckman Coulter, Krefeld, Germany). Huh7 and MDA-MB-231 cells 
were sub-cultured every three to four days. Cells were detached using 
trypsin/ethylenediaminetetraacetic acid (Trypsin/EDTA). Appropriate cell numbers were 
reseeded in either culture flasks or multiwell-plates for further experiments. For Huh7 cells, 
all culture flasks and multiwell-plates were coated with Collagen coating solution prior to 
use. 
Cells were routinely tested for contamination with mycoplasma using PCR detection kit 
VenorGeM (Minerva Biolabs, Berlin, Germany). 
2.2.1.1 Freezing and thawing 
For long-term storage in liquid nitrogen cells were washed with PBS and centrifuged 
(1 000 rpm, 5 min). 1 - 2 x 106 cells were resuspended in 1 ml freezing medium and 
transferred to cryovials. Cells were frozen at –20 °C and transferred to liquid nitrogen 
afterwards.  Table 2.4:  Medium for cell freezing 
Freezing medium  
Culture medium 70 %
FCS 20 %
DMSO 10 %
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For thawing, the content of a cryovial was dissolved in prewarmed culture medium. Cells 
were centrifuged immediately, resuspended in fresh culture medium, and transferred to a 
culture flask. For suspension cells, cell density was adjusted to 0.2 - 0.3 x 106 cells/ml. 
2.2.1.2 Isolation of PBMCs and cultivation of PDX cells 
Peripheral blood mononuclear cells (PBMCs) were isolated from anticoagulated blood 
(EDTA) friendly provided by Dr. Johanna Liebl (Department of Pharmacy, Ludwig-
Maximilians-University, Munich). Gradient centrifugation and Ficoll-Paque PLUS (GE 
Healthcare Life Sciences, Freiburg, Germany) was used for PBMC isolation according to 
the manufacturer’s protocol. PBMCs were cultured in RPMI 1640 medium supplemented 
with 20 % FCS. Patient-derived xenograft (PDX) acute lymphoid (ALL) and myeloid 
leukemia (AML) cells as well as respective growth media were generously provided by Dr. 
Irmela Jeremias (Research Unit Gene Vectors, Helmholtz Center, Munich Gene Vectors, 
Helmholtz Center, Munich). The model for PDX cell growth has been predescribed.78,79 Table 2.5:  Media for PBMC and PDX cell culturing 
PDX ALL cell medium   PDX AML cell medium 
RPMI 1640 500 ml  StemPro-34 medium 50 ml
FCS 100 ml  Nutrient supplement 1.3 ml
L-Glutamine 200 mM 5 ml  Pen/Strep 0.5 ml
Pen/Strep 5 ml  L-Glutamine 200 mM 0.5 ml
Gentamycin 50 mg/ml 1 ml  FCS 1 ml
Add to 50 ml of medium  FLT3-L 10 ng/ml
ITS 100x 300 µl  SCF 10 ng/ml
Pyruvate 100 mM 500 µl  TPO 10 ng/ml
α-TG 21.7 µl  IL-3 10 ng/ml
   
PBMC medium   
RPMI 1640 500 ml   
FCS 100 ml    
Pen/Strep 1 ml    
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2.2.2 Cell viability assays 
Cell viability was analyzed using CellTiter-BlueTM and CellTiter-GloTM Luminescent Cell 
Viability Assay (Promega, Madison, WI, USA). Experiments were carried out following the 
manufacturer’s protocol. Briefly, cells were seeded in 96-well plates and treated with the 
compounds or DMSO as indicated for different periods of time. Cell viability was 
determined by addition of CellTiter-BlueTM reagent, further two to four hours of incubation 
followed by a fluorescence readout using SpectraFluor PlusTM (Tecan, Crailsheim, 
Germany). Cellular ATP levels were measured by addition of CellTiter-GloTM reagent and 
measurement of luminescence signal using OrionII microplate luminometer (Titertek 
Berthold, Pforzheim, Germany). 
2.2.3 Colony formation assay 
For assessment of the impact of the compound on colony formation, cells were treated with 
compound as indicated or DMSO for 24 h. Cells were reseeded in 12-well plates in colony 
formation medium (5 x 103 cells/ml) and incubated for further 7 days. Colonies were 
visualized by addition of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) reagent (Promega, Madison, WI, USA) and incubation for further 2 h. Colony 
count was evaluated using ImageJ software. Table 2.6:  Medium for colony formation assay 
Colony formation medium  
Normal culture medium 60 ml
FCS 40 ml
Pen/Strep 1 ml
Methylcellulose 0.52 %
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2.2.4 Flow cytometry 
For flow cytometric measurements a FACS CantoII device (BD Biosciences, Heidelberg, 
Germany) was used. FlowJo 7.6 software (Tree Star Inc., Ashland, OR, USA) was used for 
further data analysis. Table 2.7:  Buffers and staining solutions for flow cytometry 
FACS FlowTM   FACS CleanTM 
Na2HPO4 1.0 %  NaClO 1.0 %
NaCl 0.1 %  NaOH 0.8 %
2-Phenoxyethanol 1.0 %  H2O  
NaF 1.0 %    
EDTA Na2 Dihydrate 1.0 %    
H2O     
     
PI staining solution   HFS-PI solution  
PI 5 µg/ml  Sodium citrate 0.1 %
PBS   Triton X-100 0.1 %
   PI 50 µg/ml
   PBS 
 
2.2.4.1 Propidium iodide (PI) exclusion assay  
PI exclusion assay was used to evaluate cell membrane integrity and general condition of 
cells upon treatment. Propidium iodide is not membrane permeable but can enter the cell and 
intercalate into DNA in case of cell damage and loss of membrane integrity. For PI exclusion 
assay cells were treated as indicated and incubated for different periods of time. Cells were 
collected, washed with cold PBS, pelleted (600 x g, 5 min, 4 °C), and incubated with PI 
staining solution for 5 min on ice. The PI positive population was gated in the histogram 
plot. 
2.2.4.2 Assessment of apoptotic cell death 
Cells were treated as indicated and incubated for 48 h. In case of co-treatment with 
Q-VD-OPh, the pan-caspase inhibitor was added 30 min before compound treatment. 
Apoptotic cell death was analyzed using two different methods.  
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First, cell death was measured as predescribed by Nicoletti et al.80 In brief, cells were 
collected, washed in cold PBS, pelleted (600 x g, 5 min, 4 °C), and incubated with hypotonic 
fluorochrome solution containing propidium iodide (HFS-PI solution). The amount of DNA 
within the cell depends on the stage of cell cycle and can be measured by means of the DNA 
intercalating dye PI. Apoptotic cells show a broad subG1 phase peak and were gated in the 
histogram plot (Figure 2.1). 
 
 
 
 
 
Figure 2.1: SubG1 gating in Nicoletti assay histogram plot. 
Second, cell death of PDX cells and PBMCs was determined by using forward and side 
scatter plot signals (FSC-SSC). Depending on the FSC-SSC signal, cells can be analyzed 
regarding their size (FSC) and granularity (SSC). During apoptosis, cell shrinkage and a 
higher particle content are observed which can be measured by decreased FSC and increased 
SSC signals. Viable and dead cells were gated in FSC-SSC dot plots (Figure 2.2). 
 
 
 
 
 
Figure 2.2: Viable and dead cell gating according to FSC-SSC signals and dot plot. 
Percentage of specific cell death was calculated using the formula 100 x [experimental cell 
death (%) – spontaneous cell death (%)] / [100 % - spontaneous cell death (%)].81 In order 
to assess chemosensitivity, Bliss values were calculated using the formula [specific cell 
death combined treatment / (specific cell death compound 1 + specific cell death compound 
2 –  specific cell death compound 1 x specific cell death compound 2)].82 Bliss values > 1.05 
indicate synergistic, 0.95 - 1.05 additive, and < 0.95 antagonistic effects. 
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2.2.4.3 Measurement of mitochondrial membrane potential (MMP) 
Functional mitochondria are characterized by their mitochondrial membrane potential 
(MMP) which is disturbed for example during apoptosis. For measurement of MMP, the 
cationic dye JC-1 (Enzo Life Sciences, Farmingdale, NY, USA) was used. The dye exhibits 
green fluorescence as a monomer whereas the aggregates formed in mitochondria with an 
intact membrane potential show a red fluorescent signal. For assessment of MMP, cells were 
treated with compound or DMSO for the indicated time-points. JC-1 staining solution (10x) 
was prepared in prewarmed medium. As a positive control, Carbonyl cyanide 3-
chlorophenylhydrazone (CCCP) (Sigma-Aldrich, Taufkirchen, Germany), an uncoupler of 
oxidative phosphorylation, was added during staining (50 µM). JC-1 staining solution was 
added directly to the intended wells for 30 min (37 °C, 5 % CO2) to a final concentration of 
2 µM. Red and green fluorescence were analyzed by flow cytometry. Compensation was 
performed using BD™ CompBeads Anti-Mouse Ig, κ particles and AlexaFluor488/PE 
mouse IgG2b, κ isotype control antibodies (BD Biosciences, Heidelberg, Germany). The 
compensation beads were prepared as described in the manufacturer’s manual in staining 
buffer (2 % FCS in PBS). Cells with an intact MMP were gated in dot plots (Figure 2.3). 
 
 
 
 
 
Figure 2.3: JC-1 aggregate gating in dot plot for MMP analysis. 
  
2.2 Methods 23 
2.2.4.4 Measurement of mitochondrial ROS generation 
The electron transport chain (ETC) is a major site of reactive oxygen species (ROS) 
production. For assessment of mitochondrial ROS, MitoSOXTM dye (Thermo Fisher 
Scientific, Waltham, MA, USA) was used. The staining was conducted following the 
manufacturer’s protocol. In brief, cells were treated with the compound in the indicated 
concentrations for 6 h. Antimycin A (20 µM, 45 min, 37 °C, 5 % CO2), an inhibitor of the 
ETC complex III, was used as positive control (Sigma-Aldrich, Taufkirchen, Germany). The 
dye was diluted in DMSO to 5 mM concentration and further diluted in HBSS buffer (Sigma-
Aldrich, Taufkirchen, Germany) to a 5 µM working solution. Cells were harvested, washed 
with PBS, and incubated with MitoSOXTM working solution for 30 min (37 °C, 5 % CO2). 
Further steps were conducted at 4 °C. Cells were harvested, washed with PBS, and 
resuspended in an appropriate volume of PBS. Mean fluorescence intensities (MFI) and 
histogram plots were used for evaluation of ROSmt generation. 
2.2.5 Immunoblotting 
2.2.5.1 Sample preparation and protein quantification 
Cells were treated as indicated and lysed in Milanese lysis buffer (modified RIPA buffer). 
Samples were frozen at –80°C for 15 min and centrifuged (14 000 rpm, 10 min, 4 °C). 
Protein concentrations of the lysates (supernatants) were determined using Bradford 
ReagentTM (Bio-Rad Laboratories GmbH, Munich, Germany). Absorbance was measured 
with SpectraFluor PlusTM (Tecan, Crailsheim, Germany) and protein concentrations were 
determined using linear regression. 5x sample buffer was added to each sample. Protein 
concentrations were adjusted by addition of 1x SDS sample buffer (5x sample buffer diluted 
1:5 in RIPA buffer). Protein samples were heated to 95 °C for 5 min and stored at –20 °C. 
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RIPA lysis buffer  Milanese lysis buffer 
Tris-HCl (pH 7.4)  50 mM  Na2VO3 300 µM
NaCl  150 mM  NaF 1 mM
Nonidet NP40  1 %  β-Glycerophosphate 3 mM
Deoxycholic acid  0.25 %  Pyrophosphate 10 mM
SDS  0.10 %  RIPA lysis buffer 
H2O  Add before use: 
  Complete® 4.0 mM
5x SDS sample buffer  PMSF 1.0 mM
Tris-HCl, 3.125 M, pH 6.8 10 %  H2O2 0.6 mM
SDS 5 %   
Glycerol 50 %   
DTT 2 %   
Pyronin Y 0.025 %   
H2O   
 
2.2.5.2 SDS-PAGE, tank electroblotting, and protein detection 
For SDS-polyacrylamide gel electrophoresis (SDS-PAGE), discontinuous polyacrylamide 
gels were loaded with the protein samples. The electrophoresis was performed by means of 
a Consort Electrophoresis Power Supply E835 device (Sigma-Aldrich, Taufkirchen 
Germany) with 100 V for 21 min (protein stacking) followed by 45 min at 200 V (protein 
separation). The prestained protein ladder PageRulerTM (Fermentas, St. Leon-Rot, Germany) 
was used as molecular weight marker. Protein load was measured directly after 
electrophoresis on the stain-free gel using ChemiDoc Touch Imaging System (Bio-Rad 
Laboratories GmbH, Munich, Germany). 
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Stacking gel  Separation gel 10 %/12 % 
RotiphoreseTM Gel 30  17 %  RotiphoreseTM Gel 30 33 %/40 %
Tris (pH 6.8)  125 mM  Tris (pH 8.8)  375 mM
SDS  0.1 %  SDS  0.1 %
TEMED  0.2 %  TEMED  0.1 %
APS  0.1 %  APS  0.05 %
H2O  TCE 0.05 %
  H2O 
   
Electrophoresis buffer   
Tris base 4.9 mM   
Glycine 38 mM   
SDS 0.1 %   
H2O    
After SDS-PAGE, proteins were transferred onto a nitrocellulose membrane (Hybond-
ECLTM, Amersham Bioscience, Freiburg, Germany) by tank blotting. Protein transfer was 
carried out at 4 °C, 100 V for 90 min in 1x tank buffer. Table 2.10:  Buffers for tank electroblotting 
5x Tank buffer  1x Tank buffer 
Tris base 240 mM  5x Tank buffer 20 %
Glycine 195 mM  Methanol 20 %
H2O  H2O 
 
Membranes were blocked with 5 % non-fat dry milk powder (Blotto) (Carl Roth, Karlsruhe, 
Germany) and incubated with the respective primary antibody at 4 °C overnight or at RT for 
2 h followed by incubation with the corresponding horseradish peroxidase (HRP)-
conjugated secondary antibody (1 h, RT). Protein bands were visualized using enhanced 
chemiluminescence solution (ECL) and ChemiDoc Touch Imaging System. For 
quantification of band intensity, Image LabTM Software was used (Bio-Rad Laboratories 
GmbH, Munich, Germany). 
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ECL solution 
Tris (pH 8.5) 100 mM
Luminol 2.5 mMp-Coumaric acid 1 mM
H2O2  17 µM
H2O 
 Table 2.12:  Primary antibodies 
Antigene Source Dilution Provider 
β-actin Mouse 1:1000 Merck, Darmstadt, Germany 
Caspase 3 Rabbit 1:1000 Santa Cruz Biotechnology, 
Dallas, TX, USA 
ClpP Mouse 1:1000 Abcam, Cambridge, UK 
ClpX Rabbit 1:500 Abcam, Cambridge, UK 
Hsp60 Goat 1:1000 Santa Cruz Biotechnology, 
Dallas, TX, USA 
PARP Rabbit 1:1000 Cell Signaling Technology, 
Danvers, MA, USA 
 Table 2.13:  Secondary antibodies 
Antibody Dilution Provider 
HRP, Donkey anti-goat IgG 1:1000 Abcam, Cambridge, UK 
HRP, Goat anti-mouse IgG 1:1000 Santa Cruz Biotechnology, 
Dallas, TX, USA 
HRP, Goat anti-rabbit IgG  1:1000 DIANOVA GmbH, Hamburg, 
Germany 
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2.2.6 Carbonylation assay 
For analysis of protein carbonylation the Oxidized Protein Western Blot Kit (Abcam, 
Cambridge, UK) was used according to the manufacturer’s protocol. In brief, cells were 
treated with compound or DMSO for 6 h. H2O2 treatment (1 mM, 1 h) served as positive 
control. Cells were lysed and carbonyl groups in the protein side chains were derivatized to 
2,4-dinitrophenylhydrazone (DNP-hydrazone) by treatment with 2,4-dinitrophenyl-
hydrazine (DNPH). Polyacrylamide gel electrophoresis and western blot were performed 
(see 2.2.5.2). Membranes were incubated with a primary antibody against DNP followed by 
a secondary HRP-conjugated antibody and chemiluminescence detection. 
2.2.7 Quantitative real-time PCR (q rtPCR) 
Cells were treated as indicated and total RNA was isolated using RNeasy mini Kit (Qiagen 
GmbH, Hilden, Germany) according to the manufacturer’s protocol. The concentration of the 
purified RNA was determined by means of a NanoDrop® ND-1000 spectrophotometer 
(Peqlab Biotechnology GmbH, Erlangen, Germany). The obtained RNA was re-transcribed 
into complementary DNA (cDNA) using the High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems, Foster City, CA, USA). CDNA samples were stored at 4 °C until use for 
quantitative real-time PCR (q rtPCR). A QuantStudio 3 Real-Time PCR System device (Thermo 
Fisher Scientific, Waltham, MA, USA) was used. Either TaqMan Gene Expression Master Mix 
(Life Technologies Corporation, Carlsbad, CA, USA) or SYBR Green Master Mix (Thermo 
Fisher Scientific, Waltham, MA, USA) were used depending on the utilized primer. The ClpP 
primer was also purchased from Thermo Fisher Scientific. GAPDH or actin were used as 
housekeeping genes. TaqMan primers for GAPDH were obtained from Biomers (Ulm, 
Germany). SYBR Green primers were purchased from metabion international AG 
(Planegg/Steinkirchen, Germany). Average CT values of target genes were normalized to 
control as ΔCT. Changes in RNA levels were shown as fold expression (2-ΔΔ CT) calculated 
by the ΔΔCT method. Table 2.14:  Sequences of SYBR Green primers 
Primer Forward 5’ – 3’ Reverse 5’ – 3’ 
Actin TTC ACC TAC AGC AAG GAC GA GAA CTC GAA GAT GGG GTT GA 
CHOP TTG CCT TTC TCC TTC GGG AC CAG TCA GCC AAG CCA GAG AA 
Hsp60 GGA CAC GGG CTC ATT GCG TTC TTC AGG GGT GGT CAC AG 
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2.2.8 Stable isotope labeling with amino acids in cell culture 
(SILAC) 
For SILAC experiment, K562 cells were cultured with SILAC medium (Thermo Fisher 
Scientific, Waltham, MA, USA), containing different stable isotope labeled (medium, heavy) 
or non-labeled amino acids (light). Media and amino acids were friendly provided by Prof. 
Dr. Stephan A. Sieber (Department of Chemistry, Technical University of Munich, 
Garching). Prior to compound treatment, K562 cells were cultured for 5-6 doublings in light, 
medium, and heavy labeled SILAC medium (Table 2.15).  
Labeled cells were treated with 10 µM compound for 24 and 48 h or with DMSO. Cell lysis, 
sample preparation, and quantitative mass spectrometry analysis was done by Anja Fux and 
Matthias Stahl (Department of Chemistry, Technical University of Munich, Garching). Table 2.15:  Medium for SILAC experiment  
SILAC medium 
SILAC RPMI 1640 500 ml
FCS, dialyzed, heat 
inactivated 50 ml
L-Glutamine 200 mM 5 ml
L-Arginine*  375 µl
L-Lysine* 375 µl
 
*light, medium, and heavy isotope labeled amino acids, see Table 2.16 
 Table 2.16:  Used amino acids with different isotope labeling 
Amino acid  Mass difference Isotope label Stock concentration 
L-Lys-HCl (182.65 g/mol) - - 101.92 mg/ml 
L-Lys-2HCl (223.10 g/mol) +4 2H4 106.38 mg/ml 
L-Lys-HCl (190.65 g/mol) +8 13C6, 15N2 126.73 mg/ml 
L-Arg-HCl (210.66 g/mol) - - 60.04 mg/ml 
L-Arg-HCl (216.60 g/mol) +6 13C6 61.73 mg/ml 
L-Arg-HCl (220.60 g/mol) +10 13C6, 15N4 62.87 mg/ml 
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2.2.9 Assessment of mitochondrial morphology 
For analysis of mitochondrial morphology, MDA-MB-231 cells were seeded in 8-well 
ibiTreat µ-slides (ibidi GmbH, Munich, Germany) and treated as indicated. Mitochondria 
were visualized using MitoTracker® Red CMXRos (Thermo Fisher Scientific, Waltham, MA, 
USA) according to the manufacturer´s instructions. In brief, a staining solution (1 mM in 
DMSO) was prepared. Growth medium was removed and the cells were incubated with 
staining solution (200 nM in growth medium) for 30 min (37 °C, 5 % CO2). Afterwards, the 
staining solution was replaced with fresh growth medium and mitochondrial morphology 
was assessed by live-cell imaging by means of a Leica-SP8 confocal microscope (Leica 
Microsystems, Wetzlar, Germany) in an incubation chamber at 37 °C, 80 % humidity and 
5 % CO2 (okolab S.r.l., Pozzuoli, Italy). 
For electron microscopy, Jurkat cells were treated as indicated, washed, pelleted, and fixed 
in 6.25 % glutaraldehyde. Embedding and preparation of sample sections were done by 
Sabine Schäfer (Institute of Pathology, Ludwig-Maximilians-University, Munich). Electron 
microscopy was performed in the laboratory of Prof. Dr. med. Jens Waschke (Institute of 
Anatomy and Cell Biology, Ludwig-Maximilians-University, Munich). 
2.2.10 Statistical analysis 
The experiments were performed at least three times unless otherwise indicated. Statistical 
evaluation was done by means of GraphPad Prism software (version 5.04; GraphPad Software, 
San Diego, CA, USA). Bar graphs are shown as mean ± SEM. For comparison of two groups, a 
t-test was performed. Three or more groups were compared by one-way analysis of variance 
(ANOVA) followed by Tukey’s Multiple Comparison Test unless otherwise indicated. 
Statistical significance was assumed if p < 0.05. 
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3 Results 
3.1 Characterization of functional effects of ClpXP 
inhibitors  
3.1.1 ClpXP expression in different leukemia cell lines 
In a first western blot experiment, expression of the ClpX chaperone and the ClpP peptidase 
subunit in different leukemia cell lines was determined (Figure 3.1). Both were expressed 
most prominent in the cell lines K562 (CML) and Jurkat (T-ALL). The subunits occurred to 
a lower extent in CEM cells (T-ALL). HL-60 (AML) cell line showed the lowest ClpP and 
ClpX protein levels. 
 
Figure 3.1: ClpX and ClpP subunits are expressed in various leukemia cell lines. Western blot for ClpX 
and ClpP in HL-60, K562, Jurkat, and CEM cells is shown. Bar diagram displays quantification of 
ClpX and ClpP protein expression normalized to K562 cell line. Whole protein bands served as 
loading control for quantification (n=3). 
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3.1.2 ClpXP inhibition affects cell viability 
Several above mentioned structures with different activity against ClpXP subunits or the 
whole complex were tested regarding their inhibitory properties in human leukemic cancer 
cell lines. K562 and Jurkat cells representative for leukemia cells from myeloid and 
lymphoid trait were used (Figure 3.2 A, B). In the first group of structures (319, 334, 335, 
and 339) 334 revealed to have the strongest effect on cell viability of both cell lines. 335 
showed to be least effective (Figure 3.2 A) in accordance to its activity on bacterial ClpXP 
complex but not human ClpXP complex. The second inhibitor group with activity towards 
the ClpP subunit affected cell viability of the cell lines only moderately with TG53 being 
the most potent ClpP inhibitor structure (Figure 3.2 B). In general, Jurkat cell viability was 
decreased to a greater extent than K562 cell viability. A table of IC50 values is attached 
(Appendix A.2, Figure A.1). 
 
Figure 3.2: ClpXP inhibitors affect cell viability of K562 and Jurkat cells. Cell viability of K562 and Jurkat 
cells upon indicated ClpXP/ClpX (A) or ClpP (B) inhibitor treatment is shown (72 h). 
CellTiter-BlueTM reagent was used. Viability was normalized to DMSO treated control (n=3). 
In order to characterize the most potent compound 334, an inhibitor of the ClpX subunit, 
further viability assays were performed in additional leukemia cell lines HL-60 and CEM 
(Figure 3.3). Cell viability was notably decreased in all four cell lines K562, Jurkat, CEM, 
and HL-60. HL-60 cells with the lowest ClpXP protein expression showed the lowest 
sensitivity towards the inhibitor 334.  
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Figure 3.3: ClpX inhibition decreases cell viability of various leukemic cell lines. Cell viability of HL-60, 
K562, Jurkat, and CEM cells upon ClpX inhibitor treatment (72 h) is shown. CellTiter-BlueTM 
reagent was used. Viability was normalized to DMSO treated control. Table shows IC50 values 
calculated using nonlinear regression (n=3). 
3.1.3 ClpX inhibition decreases colony formation 
For further characterization, the effect of 334 on colony formation was investigated. 
Therefore, cells were pretreated with 334, reseeded, and grown for further 7 days in the 
absence of the inhibitor. Colony formation was concentration-dependently decreased in both 
cell lines K562 and Jurkat (Figure 3.4). Notably, clonogenic growth of K562 cells was 
affected at lower inhibitor concentrations compared to Jurkat cells. 
 
 
 
 
 
 
 
 
Figure 3.4: ClpX inhibitor impairs clonogenic growth of K562 and Jurkat cells. Colonies formed by Jurkat 
cells pretreated with 334 for 24 h and grown in the absence of 334 for further 7 days are 
representatively shown in the upper panel. Bar diagram represents colony count of K562 and Jurkat 
cells normalized to solvent treated control cells (* p < 0.05, ** p < 0.01, *** p < 0.001, One-way 
ANOVA, Tukey’s Multiple Comparison Test, n=3). 
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3.1.4 ClpX inhibition induces apoptotic cell death 
Besides the impact of ClpX inhibition on cell viability and colony formation, we further 
focused on apoptotic cell death using the Nicoletti assay. Apoptotic cell death was induced 
in both cell lines at a concentration of 30 µM of the ClpX inhibitor (Figure 3.5 A). In line, 
western blot analysis showed PARP cleavage concomitant with the activation of Caspase 3 
(Figure 3.5 B) which represent further hallmarks of apoptotic cell death. Pretreatment with 
the pan-caspase inhibitor Q-VD-OPh was able to prevent K562 and Jurkat cells from cell 
death induced by high concentrations of 334 (50 µM) underlining the induction of caspase-
dependent cell death by the ClpX inhibitor (Figure 3.5 C). In contrast, HL-60 cells with low 
protein levels of ClpX and ClpP subunits were less sensitive to 334 treatment and showed 
moderate apoptosis induction at 50 µM of the ClpX inhibitor (Figure 3.5 D). 
 
Figure 3.5: ClpX inhibitor induces apoptotic cell death in K562 and Jurkat cells. (A) Bars represent cell 
death induced by 334 in the indicated concentrations after 48 h of treatment. Cell death was analyzed 
by flow cytometry using Nicoletti assay. (B) Western blot for PARP and Procaspase 3 is shown for 
K562 and Jurkat cells treated with 50 µM of 334 (24 h). Stain free whole protein bands serve as 
loading control (n=3). (C) Bars show cell death induced in cells treated with 334 (50 µM), pretreated 
with Q-VD-OPh (20 µM, 30 min) alone or a combination of 334 and Q-VD-OPh (48 h). (D) Cell 
death of HL-60 cells treated with 334 for 48 h is shown (* p < 0.05, *** p < 0.001, One-way 
ANOVA, Tukey’s Multiple Comparison Test, n=3). 
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3.1.5 ClpX inhibitor is effective in patient-derived xenograft 
(PDX) cells 
In addition to the induction of cell death in the above mentioned cell lines, the inhibitor was 
tested in patient-derived xenograft (PDX) cells generously provided by Dr. Irmela Jeremias 
(Research Unit Gene Vectors, Helmholtz Center, Munich). In this model, primary tumor 
cells from ALL or AML patients are injected into immune-compromised mice. After growth 
and the development of the leukemia, PDX cells are re-isolated and can be used for further 
analysis. Inhibitor treatment induced cell death in almost all PDX cells as well as in isolated 
peripheral blood mononuclear cells (PBMCs) representing their healthy counterpart and 
control cells (Figure 3.6 A). Western blot analysis showed the expression of ClpX and ClpP 
subunits in the used PDX cells and PBMCs (Figure 3.6 B). No correlation between ClpXP 
protein expression and sensitivity towards the inhibitor could be observed. 
 
Figure 3.6: ClpX inhibitor induces cell death in PDX cells and PBMCs. (A) Bar diagram shows specific 
cell death of PDX cells (n=1) and isolated PBMCs (n=3) treated with 334 as indicated for 48 h. Cell 
death was analyzed by flow cytometry using FSC-SSC plots. (B) Western blot for ClpX and ClpP 
protein in different PDX cells and PBMCs is shown. Whole protein bands serve as loading control 
(n=1).  
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3.1.6 ClpP inhibitors are effective in hepatocellular carcinoma 
cells 
Furthermore, cancer cells derived from other tissues such as liver could exhibit different 
sensitivity towards ClpXP inhibitors because of their distinct metabolic profile, 
mitochondrial mass, and reliance on mitochondrial function. In order to address this issue, 
cell viability and cell death of the hepatocellular carcinoma cell line Huh7 were assessed 
upon ClpP inhibitor treatment (Figure 3.7). Notably, viability of Huh7 cells was strongly 
decreased by the ClpP subunit inhibitors TG42 and TG53 which exhibited only slight effects 
in leukemia cell lines K562 and Jurkat. Moreover, TG42 and TG53 induced apoptotic cell 
death in Huh7 cells. Huh7 cells showed a medium ClpP and ClpX protein expression 
compared to K562 cells with high and HL-60 cells with low levels of the subunits (Figure 
3.7 B). 
 
Figure 3.7: Hepatocellular carcinoma cells exhibit high sensitivity towards ClpP inhibitors in terms of 
cell viability and cell death. (A) Cell viability of Huh7 cells upon indicated ClpP inhibitor treatment 
(72 h) is shown. CellTiter-BlueTM reagent was used. Viability was normalized to DMSO treated 
control. IC50 values calculated using nonlinear regression are shown (n=3). (B) Western blot for 
ClpP and ClpX subunits expression of Huh7 compared to K562 and HL-60 cells is shown. Whole 
protein bands serve as loading control (n=3). (C, D) Bars represent cell death of Huh7 cells induced 
by TG42 (C) and TG53 (D) in the indicated concentrations after 48 h of treatment. Cell death was 
analyzed by flow cytometry using Nicoletti assay (* p < 0.05, ** p < 0.01, *** p < 0.001, One-way 
ANOVA, Tukey’s Multiple Comparison Test, n=3).  
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3.2 Mechanistic studies on ClpXP inhibition 
3.2.1 ClpXP inhibition leads to a fast decline in ATP 
For further characterization of the inhibitors and better understanding of the underlying 
signaling mechanisms, additional experiments were performed with Jurkat cells. Thereby, 
the main focus was laid on mitochondrial function and integrity. The electron transport chain 
(ETC) located within the inner mitochondrial membrane is the major production site of 
cellular ATP. First, we analyzed cellular ATP levels after short inhibitor treatment using 
CellTiter-GloTM reagent (Figure 3.8 A). Compared to cellular ATP, overall cell viability 
measured by CellTiter-BlueTM was decreased to about 50 % by inhibitor concentrations 
whereas cellular ATP was completely abolished. Accordingly, the ClpP subunit inhibitor 
TG53 exhibited similar effects on ATP levels (Figure 3.8 B) suggesting a specific effect on 
mitochondrial respiration. 
 
Figure 3.8: Short-term ClpXP inhibition leads to decreased ATP levels. Diagrams show cell viability of 
Jurkat cells assessed by CellTiter-BlueTM (CTB) and cellular ATP levels measured by CellTiter-
GloTM (CTG) reagent after 3 h of ClpX (A) or ClpP (B) inhibitor treatment in the indicated 
concentrations (* p < 0.05, t-test, Holm-Sidak method,  n=3). 
3.2.2 ClpX inhibition causes ROSmt generation and protein 
carbonylation 
Physiological metabolic activity of cells is accompanied with production of low 
concentrations of mitochondrial reactive oxygen species (ROSmt) as a by-product of 
mitochondrial respiration. However, mitochondrial dysfunction, e.g., a defect in the ETC 
causes the production of high amounts of ROSmt which further affect mitochondrial integrity 
and cell fate. As inhibitor of the ETC complex III, Antimycin A promotes the production of 
ROSmt. Interestingly, ROSmt production was increased concentration-dependently by the 
ClpX inhibitor 334 (Figure 3.9 A). Further, ROS are responsible for oxidation of proteins, 
more precisely protein carbonylation. Carbonyl proteins represent a marker for oxidative 
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stress. Carbonyl groups additionally serve as tag for catalytical degradation of proteins by 
cellular peptidases. These groups can be derivatized to 2,4-dinitrophenylhydrazone and 
detected by western blot using a primary antibody against the derivatized carbonyl groups. 
ClpX inhibitor treatment led to moderate protein carbonylation in comparison to hydrogen 
peroxide treated cells (Figure 3.9 B). PI exclusion assays at short time-points of treatment 
and the indicated concentrations of the inhibitor proof the integrity of cell membrane and 
exclude that effects were due to general bad condition of the cells (Figure 3.9 C). 
 
Figure 3.9: ClpX inhibition drives mitochondrial ROS production and protein carbonylation. (A) 
Mitochondrial ROS production assessed by flow cytometry and MitoSOXTM reagent is shown as 
mean fluorescence intensity (MFI) in the bar diagram (left) and histogram plot (right). Cells were 
treated with 334 as indicated (6 h) or Antimycin A (AntiA) as positive control (20 µM, 1 h). (B) 
Western blot shows bands of carbonylated proteins after treatment with indicated concentrations of 
334 (6 h) or H2O2 serving as positive control (1 mM, 1 h). (C) Bar diagram represents PI positive 
(PI+) cells after 334 treatment for 6 h measured by flow cytometry (* p < 0.05, One-way ANOVA, 
Tukey’s Multiple Comparison Test, n=3).  
3.2.3 ClpX inhibition disrupts mitochondrial membrane potential 
The mitochondrial membrane potential (MMP) presents the potential difference across the 
inner membrane of the mitochondrion and is essential for the maintenance of mitochondrial 
ATP production. Loss of MMP is observed as an initial event in intrinsic apoptosis signaling. 
3.2 Mechanistic studies on ClpXP inhibition 38 
Former results reveal the impairment of mitochondrial function, the decrease in ATP levels, 
as well as the increase in ROSmt production. They all point to a disturbed function of the 
electron transport chain. In line, mitochondrial membrane potential assessed by JC-1 dye 
staining and flow cytometry was disturbed already after 6 h of ClpX inhibition and complete 
loss of MMP was visible at later time-points (Figure 3.10 A). PI exclusion displayed that 
cell membrane integrity was not affected at 6 h of treatment using the same inhibitor 
concentration (30 µM) but started at 24 h of treatment (Figure 3.10 B). 
 
Figure 3.10: ClpX inhibition disrupts mitochondrial membrane potential. (A) Disruption of MMP by 334 
(30 µM) at the indicated time-points is shown. Carbonyl cyanide 3-chlorophenylhydrazone (CCCP) 
served as positive control. JC-1 dye aggregates indicate mitochondria with intact MMP and were 
measured using flow cytometry. (B) PI exclusion assay for the indicated time-points of ClpX 
inhibitor treatment (30 µM) is shown (*** p < 0.001, One-way ANOVA, Tukey’s Multiple 
Comparison Test, n=3). 
3.2.4 ClpX inhibition influences proteins involved in the UPRmt 
Besides other mitochondrial proteases such as Lon protease, the role of the ClpXP protease 
in mitochondria includes the mitochondrial proteostasis. As already shown, inhibition of the 
protease promotes changes in mitochondrial energy production, mitochondrial integrity, and 
carbonylation of proteins. The focus was further laid on mitochondrial unfolded protein 
response (UPRmt) stress signaling that is thought to be regulated by, inter alia, ClpXP itself. 
A common marker of mitochondrial stress is the heat shock protein 60 (Hsp60). Notably, 
Hsp60 was found to be decreased on protein (Figure 3.11 A) and transcriptional level (Figure 
3.11 B). ClpP itself was decreased in cells treated with higher concentrations (30 µM) of 
ClpX inhibitor but only on the protein level (Figure 3.11 A). Further, quantitative real-time 
PCR revealed CHOP to be drastically elevated after 30 µM of ClpX inhibitor treatment. 
CHOP represents a common marker and transcription mediator of the mitochondrial but also 
the endoplasmic reticulum stress signaling response. On the one hand, this provides evidence 
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for general stress conditions occurring upon ClpX inhibition, but on the other hand, an 
impairment of the UPRmt signaling displayed by a missing induction of Hsp60 and ClpP. 
 
Figure 3.11: ClpX inhibition impairs Hsp60 protein and RNA and induces CHOP. (A) Western blot shows 
Hsp60 and ClpP protein expression in Jurkat cells after indicated 334 treatment (24 h) (n=3). (B) 
Bar diagrams represent RNA levels of Hsp60, ClpP, and CHOP for the indicated treatments (24 h). 
GAPDH and actin were used as housekeeping genes (* p < 0.05, *** p < 0.001, One-way ANOVA, 
Tukey’s Multiple Comparison Test, n=3). 
3.2.5 ClpX inhibition affects proteins implicated in mitochondrial 
function, stress, and DNA integrity 
Besides the above mentioned functional effects of the ClpX inhibitor and mechanistic 
studies, we aimed to identify involved signaling proteins and potential ClpXP substrates by 
quantitative mass spectrometry using stable isotope labeling with amino acids in cell culture 
(SILAC). K562 cells labeled with different amino acids (light, medium or heavy arginine 
and lysine) were treated with ClpX inhibitor 334 for 24 and 48 h. Quantitative proteomics 
using mass spectrometry was performed by Anja Fux and Matthias Stahl (Department of 
Chemistry, Technical University of Munich, Garching).  
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Figure 3.12: ClpX inhibition alters proteins involved in cellular stress, DNA integrity, transcription and 
translation processes, and metabolism. Representative scatter plot of quantitative proteomics 
mass spectrometry is shown. Light, medium, and heavy labeled K562 cells were treated with ClpX 
inhibitor (10 µM) for 24 and 48 h or with DMSO. Significantly enriched (blue) or depleted (red) 
proteins out of three independent experiments are shown (–log10 t-test difference cut-off = 1, log2 
ratio 24 h/DMSO = –1/1, n=3). 
Among the significantly changed proteins, mitochondrial as well as stress response related 
proteins were identified. Of note, proteins implicated in mitochondrial and nuclear 
translation and transcription were affected, such as mitochondrial elongation factor Ts or 
transcription initiation factor TFIID subunit 10. Furthermore, DNA-3-methyladenine 
glycosylase and DNA polymerase delta catalytic subunit implicated in DNA repair were 
found to be depleted. Notably, mitochondrial carnitine O-palmitoyltransferase 2 taking part 
in β-oxidation and cytoplasmic hydroxymethylglutaryl-CoA synthase were enriched which 
point to changes in cellular metabolism. Proteins significantly altered are summarized in 
Table 3.1 and 3.2. A complete list of further altered proteins identified by this approach is 
attached (Appendix A.3, Table A.1/A.2).  
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Protein ID Enriched Relevance 
H0YNJ9 Deoxyuridine 5´-triphosphate 
nucleotidohydrolase, mitochondrial 
Nucleotide metabolism 
D3DQF6 RNA-binding protein 27  
B7Z374 Gephyrin Molybdenum cofactor 
synthesis 
B0FTY2 NudC domain-containing protein 3 Stability of dynein 
Q8N995 Hydroxymethylglutaryl-CoA synthase, 
cytoplasmic 
Cholesterol synthesis  
B4E1N1 Armadillo repeat-containing protein 6  
C9J0I9 Nuclear-interacting partner of ALK Zinc-ion binding 
A0A140VKA9 Dihydropteridine reductase Phe-decomposition, amino 
acid metabolic process 
A2BDK6 Microtubule-associated protein 1B Microtubule cytoskeleton 
organization 
Q92917 G patch domain and KOW motifs-
containing protein 
Nuclear RNA-binding 
protein, pre-mRNA 
splicing 
A0A0C4DG88 POU domain protein Transcription factor 
activity 
Q53GE2 F-actin-capping protein subunit alpha-2 Actin-filament capping 
B2RDU4 Pentatricopeptide repeat domain-
containing protein 3, mitochondrial 
RNA-binding and 
mitochondrial translation 
regulation 
B2RAH5 Protein phosphatase 1 regulatory subunit Phosphatase regulator 
activity, signal 
transduction 
B4DEI4 Golgi reassembly-stacking protein 2  
Q7L0Y3 Mitochondrial ribonuclease P protein 1 Mitochondrial tRNA 
processing and 
methylation 
A0A140VK13 Carnitine O-palmitoyltransferase 2, 
mitochondrial 
Fatty acid import in 
mitochondria, β-oxidation 
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Protein ID Depleted Relevance 
E9PPY4 G patch domain-containing protein 4 Nucleic acid binding 
I3L2L5 Protein FAM195B MAPK-regulated corepressor-
interacting protein 1 
Q5T6U8 High mobility group AT-hook 1 DNA binding, transcription 
regulation 
Q5BKZ1 DBIRD complex subunit ZNF326 Transcription-, alternative 
splicing-regulation 
C9J5N1 Alanyl-tRNA editing protein Aarsd1 Alanyl-tRNA amino acylation 
P49750 YLP motif-containing protein 1 Transcription repressor, 
reduction of telomerase 
activity during embryonic 
stem cell differentiation 
V9HWG0 Chromobox protein homolog 5 Heterochromatin-formation 
Q1W6H1 DNA-3-methyladenine glycosylase Base excision repair 
Q12962 Transcription initiation factor TFIID 
subunit 10 
Transcription coactivator 
A0A024R912 Uridine-cytidine kinase 2 CTP salvage pathway 
E5KS95 Elongation factor Ts, mitochondrial Translation elongation 
H3BRL3 Ubiquitin domain-containing protein 
UBFD1 
 
B2RDW9 GTP-binding protein 1  
A0A024R4F4 DNA polymerase delta catalytic 
subunit 
Base excision repair, gap-
filling, DNA replication 
proofreading 
 
3.2.6 ClpX inhibition affects mitochondrial morphology 
Furthermore, we focused on mitochondrial morphology because the dynamic organelles 
underlie, e.g., fusion and fission dynamics in order to adapt to cellular stress conditions. 
Therefore, we performed live-cell imaging using MitoTracker® Red CMXRos to stain 
mitochondria and electron microscopy (Figure 3.13). Mitochondria of control cells showed 
to be near the nucleus, whereas the staining of ClpX inhibitor treated cells appeared to be 
more diffuse (Figure 3.13 A). Likewise, electron micrographs revealed similar observations 
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concerning localization of the mitochondria (Figure 3.13 B) with slight effects on 
mitochondrial size and shape. However, no prominent effects were observed in terms of 
fusion or fission dynamics upon ClpX inhibition. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13: ClpX inhibition slightly affects mitochondrial morphology. (A) Confocal stainings show 
mitochondria of MDA-MB-231 cells treated with 334 or DMSO as indicated for 24 h. Mitochondria 
were visualized using MitoTracker® Red CMXRos (n=3). (B) Electron micrographs display Jurkat 
cells treated with 334 (20 µM) or DMSO for 24 h. White arrows indicate mitochondria (n=1). 
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3.3 ClpX inhibition enhances chemosensitivity of 
leukemia cells 
Previous results revealed cell death induction by the compound 334 in several leukemic 
cancer cell lines as well as in PDX cells. Notably, the cell line with the lowest ClpXP protein 
expression, HL-60, exhibited low sensitivity towards the ClpX inhibitor emphasizing the 
selective effect of the compound on cells expressing the target protein. In contrast, analysis 
of cell death of PDX cells revealed no obvious correlation between ClpXP protein expression 
and sensitivity towards 334. Furthermore, PBMCs were also sensitive towards the inhibitor 
and expressed ClpX to a comparable extent. As a consequence, treatment with the inhibitor 
in cell death inducing concentrations may be problematic if the expression of ClpXP and 
sensitivity towards the inhibitor of non-cancer cells is similar to tumor cells. 
Moreover, ClpX inhibitor treatment revealed to induce protein carbonylation, mitochondrial 
dysfunction, and overall cellular stress conditions, which is underlined by the previously 
shown mechanistic effects and the proteome data. Hence, we aimed to interfere with 
mitochondrial metabolism and proteostasis to sensitize tumor cells towards common 
cytostatic drugs. Low inhibitor concentrations (10 µM) were used to trigger mitochondrial 
stress in order to enhance the cancer cells’ susceptibility to cell death. As shown in 
Figure 3.14, sensitivity of K562 cells towards the tyrosine kinase inhibitor imatinib increased 
the most in combination with the ClpX inhibitor. Mitochondrial stress induced by ClpX 
inhibition in combination with other chemotherapeutics such as etoposide or vincristine led 
to an increased cell death induction in Jurkat, CEM, and even vincristine-resistant CEM cells 
(VCR-CEM). 
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Figure 3.14: ClpX inhibitor sensitizes leukemia cells towards chemotherapy. Bars represent specific cell 
death induced in K562, Jurkat, CEM, and vincristine-resistant CEM cells (VCR-CEM). Cells were 
treated as indicated with 334 (10 µM), imatinib (Ima; K562), etoposide (Eto; Jurkat), and vincristine 
(VCR; CEM and VCR-CEM) alone or in combination for 48 h. Cell death was measured by flow 
cytometry using Nicoletti assay. Bliss values calculated for the combined chemotherapy display the 
extent of synergism. Values above 1.05 indicate synergistic effects (n=3).  
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Furthermore, we analyzed if chemosensitivity of HL-60 cells, which poorly responded to the 
ClpX inhibitor in viability and cell death assays, was enhanced by 334 treatment. Likewise, 
the inhibitor in low (10 µM) and high (50 µM) concentrations did not enhance sensitivity of 
the cells towards etoposide or cytarabine (Figure 3.15). 
 
Figure 3.15: ClpX inhibitor does not enhance chemosensitivity of HL-60 cells. Bars represent specific cell 
death induced in HL-60 cells treated as indicated with 334 (10 µM and 50µM), etoposide (Eto), and 
cytarabine (Cyt) alone or in combination for 48 h. Cell death was measured by flow cytometry using 
Nicoletti assay. Bliss values calculated for the combined chemotherapy display the extent of 
synergism. Values above 1.05 indicate synergistic effects (n=3). 
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4 Discussion 
4.1 Targeting mitochondria as anti-cancer strategy 
This thesis outlines the inhibition of the mitochondrial ClpXP protease as a novel and 
promising anti-cancer strategy. Aside from conventional cytostatic therapy, the 
mitochondrion has gained attention as a new target for cancer treatment. Therefore, the 
organelle harbors various structures to interfere with. One possibility is to address the 
intrinsic apoptosis signaling. BH3 mimetics such as ABT-263 which bind anti-apoptotic 
Bcl-2 family proteins, e.g., Bcl-2 or Bcl-xL and thereby trigger apoptosis, are currently in 
clinical trials. They are evaluated in various cancer types ranging from hematological 
malignancies to solid tumors such as colon or pancreatic cancer and have shown promising 
results so far.83 Besides mitochondrial apoptosis signaling, the mitochondrial energy 
production provides possible targets for anti-cancer drugs. As an example, the antidiabetic 
drug metformin revealed anti-tumor effects and showed to be an inhibitor of complex I of 
the electron transport chain (ETC).84 Other ETC inhibitors such as VLX600 also aim to 
affect metabolic flexibility of cancer cells and have been reported to eradicate quiescent 
tumor cells.84 
Alternatively, the interference with mitochondrial proteostasis is a novel option aside from 
targeting the mitochondrial cell death machinery or energy metabolism. Proper 
mitochondrial function relies on an efficient folding, quality control, and degradation of 
proteins imported and synthesized in the mitochondrion, which is regulated by chaperones 
and proteases.49-52 For example, the small molecule gamitrinib specifically acts as an 
inhibitor of Hsp90/TRAP-1 (heat shock protein 90, TNF receptor associated protein 1). The 
mitochondrial chaperone is responsible for ETC complex II stability and regulates opening 
of the mitochondrial permeability transition pore that mediates mitochondrial swelling and 
also induction of cell death.85,86 Similarly, the mitochondrial heat shock protein 60 (Hsp60), 
another mitochondrial chaperone, presents an attractive target with regard to mitochondrial 
proteostasis. Hsp60, together with other chaperones, permits proper folding and assembly of 
newly synthesized or imported preproteins in the mitochondrial matrix. Further, the 
chaperone is transcribed in the course of the mitochondrial unfolded protein response 
(UPRmt) to restore proteostasis.71,87 Overexpressed in a large number of tumors, Hsp60 
crosstalks with the mitochondrial apoptosis machinery by stabilization of anti-apoptotic 
survivin and interacts with the tumor suppressor p53 to suppress its pro-apoptotic activity.88 
Hence, the mitochondrion provides various promising target structures to counteract the 
development and progression of oncological diseases. 
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4.2 Targeting mitochondrial proteostasis by ClpXP 
inhibition 
Herein, we introduce another crucial part of the mitochondrial proteostasis maintaining 
network, the protease ClpXP, as a drugable target for cancer therapy. Recent reports 
stunningly demonstrated ClpXP’s role in cancer, for example, in acute myeloid leukemia, 
prostate, and breast cancer cells.54,56 Most of the recent studies were performed by ClpP or 
ClpX subunit silencing or overexpression. As targeting ClpXP in human cancer displays a 
very novel approach, appropriate compounds to inhibit ClpXP are missing so far. 
Initial characterization of various ClpXP inhibitor compounds and their derivatives 
identified in high-throughput screenings by the group of Prof. Dr. Stephan A. Sieber 
demonstrated their effectivity in various leukemia cell lines regarding cell viability. This is 
in line with other studies proposing decreased cell viability and growth upon ClpP 
knockdown or inhibition. Accordingly, Seo et al. described lower levels of cell cycle 
regulating cyclins and aberrant reactive oxygen species (ROS) production explaining for the 
proliferation inhibition.54,56,89 In terms of cell viability, ClpP subunit inhibitors exhibited 
weaker effects than ClpX or ClpXP inhibitors which may be due to the lower stability of the 
phenyl ester compounds. Consequently, a statement whether targeting of the chaperone 
subunit ClpX, the peptidase ClpP subunit or the whole ClpXP complex is the most effective 
strategy, is difficult. As previously shown by others, silencing of ClpP or ClpX exhibited 
similar effects on tumor cell proliferation and clonogenicity and may additionally depend on 
cell type.56 Thus, targeting of either the subunits or the whole complex may present an 
efficient way to inhibit ClpXP which offers more possibilities for the development of novel 
inhibitor compounds.  
Further characterization of the ClpX inhibitor 334 revealed its anti-leukemic effects in terms 
of colony formation, an indicator for tumorigenicity, and the induction of caspase-dependent 
apoptosis. Of note, sensitivity towards the inhibitor correlated with ClpXP expression that 
is reflected in a less pronounced apoptosis induction of the HL-60 cell line compared to 
K562 and Jurkat cell lines. Accordingly, the inhibitor induced cell death in various patient-
derived xenograft AML and ALL cells but also in control PBMCs which expressed the target 
ClpX to a comparable extent. Hence, applicability of ClpXP inhibitors in higher doses may 
be critical if protein expression in tumor cells does not differ greatly from healthy tissue 
counterparts. Thus, toxicity, tumor-targeted or local application of the inhibitors, and 
possible combinations with other drugs to lower the inhibitor dose need to be evaluated. 
Consistent with other reports, ClpXP targeting impaired mitochondrial integrity and 
function. Accordingly, we showed an early decrease of cellular ATP levels upon short-term 
ClpX and ClpP inhibition displaying a decreased mitochondrial respiration. As previously 
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described, ClpX and ClpP silencing disturbed ETC complex II activity and folding of its 
succinate-dehydrogenase subunit B concomitant with lowered oxygen consumption rates of 
cancer cells.54,56 According to the effect on energy metabolism, ClpX inhibition led to the 
aberrant production of mitochondrial reactive oxygen species (ROSmt) and a loss of 
mitochondrial membrane potential. As a consequence of elevated ROSmt, we revealed an 
increase of carbonyl proteins upon ClpX inhibition. The accumulation of oxidized proteins 
may be another cause for the observed functional effects such as apoptosis induction. Protein 
carbonylation leads to protein aggregation, disturbed proteostasis, and is linked to cell 
ageing.90 Further, the implication of accumulating carbonyl proteins was described to be 
involved in neurodegenerative diseases and cell death.91-93 These data confirm the inhibitors’ 
effect on mitochondrial function and simultaneously reinforce ClpXP as a drugable target. 
4.3 Mitochondrial unfolded protein response and 
chemosensitization 
ClpXP was described to be implicated in the UPRmt, a mitochondrion-to-nucleus signaling 
triggered by unfolded proteins exceeding the capacity of the mitochondrial chaperones and 
proteases network.73,74 The retrograde signaling includes nuclear transcription of chaperones 
and proteases, e.g., Hsp60 and ClpP, preventing excessive protein stress and organelle 
damage and therefore promoting cell survival.71 Only recently, ClpP knockdown was shown 
to suppress the induction of Hsp60 upon doxycycline induced UPRmt in mouse myoblasts.89 
As crucial part of the mitochondrial protein quality control network, ClpXP maintains 
proteostasis. Consequently, our data suggest that ClpXP inhibition triggers protein stress 
which is displayed by the increase of carbonyl proteins. Further, ClpXP inhibition enhanced 
chemosensitivity towards diverse cytostatic drugs, such as imatinib, a tyrosine kinase 
inhibitor, etoposide, a topoisomerase II inhibitor, and vincristine, a microtubule 
polymerization blocker. In line, ClpP was proposed to mediate cisplatin resistance in a 
cervical and hepatoma cell line lately. The authors postulated an enhanced expression of 
copper efflux pumps upon ClpP overexpression driving cisplatin export. Consistently, 
copper transport systems were reported to be involved in multidrug resistances including 
also etoposide and vincristine.94  
Our proteomics data suggest that ClpXP inhibition modulates mitochondrial proteins, 
transcription and translation processes, stress related proteins, as well as proteins implicated 
in DNA repair and integrity. Of note, accumulating stress, for example, aggregated proteins 
or missing flexibility of energy metabolism caused by ClpXP inhibition may sensitize cancer 
cells to the cytostatic drugs. Accordingly, Seo et al. showed an increased sensitivity of tumor 
cells to oxidative stress, glucose or amino acid deprivation upon ClpXP silencing.56 Further, 
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the decrease of the UPRmt-specific chaperone Hsp60 and the missing induction of ClpP 
reinforce the hypothesis of a suppressed pro-survival UPRmt signaling upon ClpXP 
inhibition. Concluding, we propose rather a general induction of cellular stress concomitant 
with an attenuated UPRmt which enhance susceptibility to cell death and chemosensitivity of 
cancer cells. 
4.4 Challenges, efforts, and future perspectives 
This thesis investigates the mitochondrial ClpXP complex as a drugable target in cancer 
therapy and introduces a set of novel structures with activity against human ClpXP. Despite 
previously shown effects of the inhibitors in various leukemia cells, there are several 
challenges yet to overcome. Diverse questions arise regarding the selective effect of the 
compounds on cancer cells, their toxicity, and potential side-effects of ClpXP targeting. 
Further issues of interest include the investigation of tumor cells that specifically respond to 
ClpXP targeting and the identification of the optimal drug partners for ClpXP inhibitors to 
enhance their anti-tumor effects. 
4.4.1 On-going studies 
In order to address these issues and to establish ClpXP targeting and appropriate inhibitor 
compounds as anti-cancer agents, there are still on-going studies on the presented inhibitors 
in our laboratory. We are currently verifying the ClpP inhibitors’ specifity towards the target 
protein ClpP by means of confocal microscopy. Therefore, the inhibitor probes are 
visualized by a copper-catalyzed cycloaddition with rhodamine-azide (click chemistry) and 
co-localization with mitochondria is analyzed. Additionally, the role of ClpXP complex in 
mtDNA integrity is still elusive. Lon protease, for example, is known to bind and stabilize 
mitochondrial DNA.95 We plan to address this issue by means of immunoprecipitation with 
mtDNA and ClpX/ClpP. Investigations on mtDNA damage, e.g., caused by ROS, using a 
qPCR approach to measure lesions represents another issue of interest.96  
Due to limited knowledge of the protease’s involvement in the retrograde UPRmt signaling, 
the identification of ClpXP substrates or peptides released from mitochondria represents a 
further currently studied and unanswered matter. Peptides released from isolated and ClpP 
inhibitor treated mitochondria are analyzed by mass spectrometry by the group of Prof. Dr. 
Stephan A. Sieber at the moment.97 Furthermore, due to the high selectivity of the ClpP 
subunit inhibitors, their use as a diagnostic tool is conceivable. 
The question whether cancer cells with a strong dependence on oxidative phosphorylation 
exhibit higher sensitivity towards ClpXP inhibitors is another field of interest. If so, ClpXP 
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targeting could be attractive in terms of eradication of quiescent cancer cells which often 
account for tumor recurrence and therapy resistance. To address this issue, comparison of 
sensitivity of different cancer cell lines towards ClpXP inhibitors could give further 
information. Cell viability and cell death assays in Huh7 cells, a hepato carcinoma cell line, 
revealed a stronger sensitivity towards ClpP inhibitors compared to leukemia cells. Along 
this line, the ClpX inhibitor exhibited a proliferation inhibiting effect in sorafenib resistant 
Huh7 cells (done by Martina Meßner, data not shown) that poorly responded to any other 
cytostatic drug, such as doxorubicin, SN38 or cisplatin. The identification of cancer types 
which predominantly respond to ClpXP inhibition or a correlation of the response to ClpXP 
inhibitors with a specific metabolic profile could open up new possibilities for personalized 
cancer therapy. 
4.4.2 Challenges and future perspectives 
ClpXP targeting may represent an attractive new strategy to address metabolic flexibility of 
tumor cells. A switch from aerobe glycolysis to oxidative phosphorylation in case of glucose 
starvation characterizes distinct tumor subpopulations with high drug resistance and 
tumorigenicity.40-45 Seo et al. reported a compensatory switch to glycolysis upon ClpP 
silencing. Simultaneously, replacement of glucose by galactose, which forces oxidative 
phosphorylation, enhanced anti-proliferative effects of ClpXP silencing.56 This underlines 
the potential application of ClpXP targeting compounds in combination with inhibitors of 
other energy pathways. Based on our chemosensitivity and proteome data the combination 
of ClpXP inhibitors with other cytostatic drugs is conceivable. Regarding the decreased 
DNA repair and integrity due to ClpXP inhibition, the combination with DNA-damaging 
agents may be beneficial. Exploiting other effects of the compounds such as the increased 
ROSmt production, e.g., by combination with inhibitors of mitochondrial anti-oxidant 
pathways, presents another attractive possibility. 
Finally, toxicity of the compounds and side effects of ClpXP inhibition need to be evaluated 
in the future. It is still elusive if a therapeutic window for ClpXP targeting drugs can be 
established. Notably, non-cancerous PBMCs as well as endothelial cells (data not shown) 
responded to the ClpX inhibitor making its applicability as single agent in high doses or 
systemic treatment questionable. So far, there is not much knowledge of possible side effects 
of ClpXP inhibition. As Cole et al. reported, mice treated with their β-lactone inhibitor 
showed no liver, muscle or renal toxicity.54 With respect to the differences of their chemical 
structure and thus stability of the various inhibitor compounds, a comparison with our 
inhibitors or general conclusions should be drawn with caution.  
Moreover, homozygous deletion of another mitochondrial matrix protease, Lon, is lethal in 
early embryonic phase.59 In comparison, mice with ClpP knockout only showed shortened 
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pre-/post-natal survival and growth retardation. Furthermore, movement and respiratory 
activities were slightly impaired. ClpP knockout mice exhibited normal hematopoiesis but 
were infertile and displayed auditory defects.54,98 In vivo studies on ClpX deletion are 
completely missing. 
Besides mitochondrial dysfunction, increased oxidative stress, loss of ClpP in mouse 
myoblasts inhibited protein translation, cell proliferation, and differentiation in vitro.89 It 
stays elusive if healthy tissues with high mitochondrial mass, such as liver, heart, and 
muscles, are predominantly affected by the inhibitors in contrast to others. Due to the lack 
of compounds for pharmacological ClpXP inhibition, studies regarding side-effects and 
toxicity are missing so far and will be of particular interest for establishment of ClpXP 
inhibitor based cancer treatment. 
In summary, this thesis presents the protease ClpXP as a drugable anti-cancer target by 
introduction and characterization of novel ClpXP inhibitors. As crucial part of the 
mitochondrial proteostasis network, ClpXP contributes to cancer cell viability, 
tumorigenicity, and cellular survival by maintenance of mitochondrial function and driving 
the pro-survival UPRmt signaling. Therefore, we elucidated various intriguing effects of 
ClpXP inhibition, for example, an enhanced chemosensitivity of cancer cells. There is now 
great interest in the development and improvement of ClpXP inhibitors in order to exploit 
ClpXP’s key role in mitochondrial function and integrity. Concluding, this thesis provides 
evidence that ClpXP inhibition may serve as an attractive and potential anti-cancer strategy 
in the future. 
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A.1 Abbreviations 
α-TG α-Thioglycerol 
AAA ATPase associated with diverse cellular activities 
ALL Acute lymphoid leukemia 
AML Acute myeloid leukemia 
ANOVA Analysis of variance 
AntiA Antimycin A 
APS Ammonium persulfate 
ATP Adenosine triphosphate 
Bcl-2 B-cell lymphoma 2 
BH3 Bcl-2 homology domain 3 
Bcr-Abl Breakpoint cluster region-Abelson 
BSA Bovine serum albumin 
Caspase Cysteinyl-aspartate specific protease 
CCCP Carbonyl cyanide 3-chlorophenylhydrazone 
Cdk5 Cyclin-dependent kinase 5 
CHOP CCAAT7-enhancer-binding protein (C/EBP) 
homologous protein  
ClpP Caseinolytic peptidase proteolytic subunit 
ClpX Caseinolytic peptidase X homolog 
CLL Chronic lymphoid leukemia 
CML Chronic myeloid leukemia 
CTB CellTiter-BlueTM 
CTG CellTiter-GloTM 
DMSO Dimethyl sulfoxide 
DNA, mt Deoxyribonucleic acid, mitochondrial 
DNP 2,4-dinitrophenyl 
DNPH 2,4-dinitrophenylhydrazine 
DTT Dithiothreitol 
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ECL Enhanced chemiluminescence 
EDTA Ethylenediaminetetraacetic acid 
EMT Epithelial-mesenchymal transition 
ETC Electron transport chain 
FACS Fluorescence activated cell sorting 
FCS Fetal calf serum 
FLT3-L FMS-like tyrosine kinase 3 ligand 
Foxo1 Forkhead-box-protein O-1 
FSC Forward scatter 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
h hour(s) 
HBSS Hanks’ Balanced Salt Solution 
HCl Hydrogen chloride 
HFS Hypotonic fluorochrome solution 
HRP Horseradish peroxidase 
Hsp60 Heat shock protein 60 
HTS High-throughput screening 
IC50 Half maximal inhibitory concentration 
IgG Immunoglobulin G 
IL-3 Interleukin-3 
IMDM Iscove’s Modified Dulbecco’s Medium 
ITS Insulin-transferrin-selenium 
JC-1 5,5′,6,6′-tetrachloro-1,1′,3,3′-
tetraethylbenzimidazolylcarbocyanine iodide 
L-Arg HCl L-Arginine monohydrochloride 
L-Lys HCl, L-Lys 2HCl L-Lysine monohydrochloride, -dihydrochloride 
min minute(s) 
MMP Mitochondrial membrane potential 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide 
PARP Poly (ADP-ribose) polymerase 
PBMC Peripheral blood mononuclear cell 
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PBS Phosphate buffered saline 
PCR, q, rt  Polymerase chain reaction, quantitative, real-time 
PDX Patient-derived xenograft 
PE Phycoerythrin 
Pen/Strep Penicillin/streptomycin 
PI Propidium iodide 
PMSF Phenylmethanesulfonyl fluoride 
Q-VD-OPh (3S)-5-(2,6-Difluorophenoxy)-3-[[(2S)-3-methyl-1-
oxo-2-[(2-quinolinylcarbonyl)amino]butyl]amino]-4-
oxo-pentanoic acid hydrate 
RIPA Radioimmunoprecipitation assay buffer 
RNA Ribonucleic acid 
ROSmt Reactive oxygen species, mitochondrial 
RPMI Roswell Park Memorial Institute 
RT Room temperature 
Sa Staphylococcus aureus 
SCF Stem cell factor, c-Kit ligand 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis 
SEM Standard error of the mean 
SILAC Stable isotope labeling with amino acids in cell 
culture 
SSC Side scatter 
TCE 2,2,2-Trichlorethanol 
TEMED Tetramethylethylenediamine 
TIC Tumor-initiating cell 
TIM Translocase inner membrane 
TOM Translocase outer membrane 
TPO Thrombopoietin 
TRAP-1 TNF-receptor associated protein 1 
Tris Tris-(hydroxymethyl)-aminomethane 
UPRmt Unfolded protein response, mitochondrial 
w/o without 
A.3 Proteome data (SILAC) 62 
A.2 IC50 values of ClpXP inhibitor compounds 
 
 
 
 
 
 
 
Figure A.1: IC50 values of ClpXP inhibitors in K562 and Jurkat cells. Cell viability of K562 and Jurkat 
cells upon inhibitor treatment (72 h) served for IC50 value calculation using nonlinear regression. 
CellTiter-BlueTM reagent was used. Viability was normalized to DMSO treated control (n=3). n.c. 
not calculated. 
A.3 Proteome data (SILAC) 
Tables A.1 and A.2 summarize proteome results for ClpX inhibitor treated K562 cells for 24 
and 48 h (–log10 t-test difference cut-off = 0, log2 ratio (24h or 48 h/DMSO) = –1.5/+1.5).  Table A.1:  Enriched proteins after 24 and 48h of ClpX inhibitor treatment versus DMSO treated control 
Protein ID Enriched Relevance 
D3DQF6* RNA-binding protein 27  
B7Z374 Gephyrin Molybdenum cofactor 
synthesis 
Q8N995 Hydroxymethylglutaryl-CoA synthase, 
cytoplasmic 
Cholesterol synthesis  
B4E1N1 Armadillo repeat-containing protein 6  
Q92917 G patch domain and KOW motifs-
containing protein 
Nuclear RNA-binding 
protein, pre-mRNA 
splicing 
Q53GE2 F-actin-capping protein subunit alpha-2 Actin-filament capping 
F5H7R9 Parathymosin  
Q8TCJ8 Glutamate-rich WD repeat-containing 
protein 1 
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Q9H9T3 Elongator complex protein 3 Histone acetylation 
C9JTT8 BET1 homolog Vesicular transport from 
ER to Golgi 
Q0P685* Eyes absent homolog 3 Tyrosine-phosphatase 
activity 
A0A140VK13* Carnitine O-palmitoyltransferase 2, 
mitochondrial 
Fatty acid import in 
mitochondria, β-oxidation 
B1Q3B3 Ferritin light chain Iron storage in a soluble, 
readily available form 
B4DGV1 Inositol hexakisphosphate / 
diphosphoinositol-pentakisphosphate 
Apoptosis, vesicle 
trafficking and 
cytoskeletal dynamics 
Q8WTW2 N-Myc-interactor  
H0Y9G6 39S ribosomal protein L3, mitochondrial  
A0A0C4DGZ0 DNA-directed RNA polymerase II 
subunit RPB1 
 
A0A0A6YYC7 E3 ubiquitin-protein ligase ZFP91  
B7Z5N7 Sec1 family domain-containing protein 1 Vesicle docking involved 
in exocytosis 
C9JKQ2 NADH dehydrogenase [ubiquinone] 1 β 
subcomplex subunit 3 
Respiration complex 
Q9H1A4 Anaphase-promoting complex subunit 1 Cell cycle progress 
Q71UI9* Histone H2A  
Q0D2M2 Histone H2B  
E7END7* Ras-related protein Rab-1A Oncogene 
B4E380 Histone H3  
B2R4R0 Histone H4  
B4DRA5 Protein transport protein Sec23B ER to Golgi vesicle-
mediated transport 
B0YJ76 Dihydrofolate reductase, mitochondrial  
K7EK35 Signal transducer and activator of 
transcription 5A 
 
B7ZKR8* Ubiquitin carboxyl-terminal hydrolase 48 Deubiquitinylation 
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Q9Y5J9* Mitochondrial import inner membrane 
translocase subunit Tim8 B 
 
Q53FC7* Heat shock 70 kDa protein 6  
H3BTL1 Microtubule-associated proteins 1A/1B 
light chain 3B 
 
A0A087X2D8 C-Jun-amino-terminal kinase-interacting 
protein 4 
 
P80217 Interferon-induced 35 kDa protein  
F5GX99 Caseinolytic peptidase B protein homolog  
A0A090N7U2 Cytosolic 5-nucleotidase 3A 
 
 
V9HW45 Pyridoxine-5-phosphate oxidase  
P56381 ATP synthase subunit epsilon, 
mitochondrial 
 
B7Z4U6 Gelsolin Actin-binding protein, 
depolymerization 
A0A0S2Z4X1 RNA-binding protein 10  
Q9BRF8 Serine/threonine-protein phosphatase 
CPPED1 
 
Q96C86 m7GpppX diphosphatase  
H0Y9P1 BMP-2-inducible protein kinase  
A0A024R3V4 Peptidyl-prolyl cis-trans isomerase  
P05204 Non-histone chromosomal protein HMG-
17 
 
* Identified in 24 and 48 h treatment 
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Protein ID Depleted Relevance 
Q5BKZ1* DBIRD complex subunit ZNF326 Transcription / alternative 
splicing-regulation 
C9J5N1 Alanyl-tRNA editing protein Aarsd1 Alanyl-tRNA amino 
acylation 
V9HWG0* Chromobox protein homolog 5 Heterochromatin-
formation 
Q1W6H1 DNA-3-methyladenine glycosylase Base excision repair 
E9PPY4* G patch domain-containing protein 4  
A0A024R912 Uridine-cytidine kinase 2 CTP salvage pathway 
E9PS41 WD repeat-containing protein 74  
Q9BSH4 Translational activator of cytochrome c 
oxidase 1 
 
Q96ST3* Paired amphipathic helix protein Sin3a Corepressor; antagonizes 
Myc oncogenic activities 
P60468* Protein transport protein Sec61 subunit β Protein translocation in the 
ER 
A0A024RBD0 Diphosphoinositol polyphosphate 
phosphohydrolase 2 
Signal transduction 
A0A0S2Z3V0 Apolipoprotein E Fatty acids and cholesterol 
transport 
A0A024R4F4 DNA polymerase delta catalytic subunit DNA repair, damage 
response 
B4DUE1 DNA ligase  
Q5VTR2 E3 ubiquitin-protein ligase BRE1A  
Q9BU61 NADH dehydrogenase [ubiquinone] 1 
alpha subcomplex assembly factor 3 
Mitochondrial ETC 
complex 1 assembly 
Q6FG43 Flotillin-2 Located in lipid-rafts, 
tumor progression, 
metastasis 
Q16643 Drebrin Actin-binding protein, 
polymerizing 
* Identified in 24 and 48 h treatment 
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cells 
I am thankful for the opportunity I had to work on another project during the last years. 
Before I started with the investigations on ClpXP inhibitors, I continued my studies on the 
role of Cyclin-dependent kinase 5 (Cdk5) in tumor-initiating cells (TICs), a project started 
by Siwei Zhang during his Ph.D. in Prof. Dr. Vollmar’s group. In addition to several 
functional effects of Cdk5 silencing and inhibition, I further focused on the impact of Cdk5 
on tumorsphere formation and on the underlying signaling. I elucidated a novel mechanism, 
the Cdk5-Foxo1-Bim axis, which mediates cell death of TICs. Please find the original article 
attached which was successfully published in the British Journal of Cancer in February 
2017. 
Mandl, M. M. et al. Inhibition of Cdk5 induces cell death of tumor-initiating cells. British journal of cancer, doi:10.1038/bjc.2017.39 (2017). 
 
 
 
 
 
 
 
 
 
  
Inhibition of Cdk5 induces cell death of
tumor-initiating cells
Melanie M Mandl1, Siwei Zhang1, Melanie Ulrich1, Elisa Schmoeckel2, Doris Mayr2, Angelika M Vollmar1
and Johanna Liebl*,1
1Department of Pharmacy, Pharmaceutical Biology, Ludwig-Maximilians-University of Munich (LMU), Butenandtstr 5-13, Munich
81377, Germany and 2LMU Hospital, Institute of Pathology, Ludwig-Maximilians-University of Munich (LMU), Thalkirchnerstrae 36,
Munich 80337, Germany
Background: Tumour-initiating cells (TICs) account for chemoresistance, tumour recurrence and metastasis, and therefore
represent a major problem in tumour therapy. However, strategies to address TICs are limited. Recent studies indicate Cdk5 as a
promising target for anti-cancer therapy and Cdk5 has recently been associated with epithelial–mesenchymal transition (EMT).
However, a role of Cdk5 in TICs has not been described yet.
Methods: Expression of Cdk5 in human cancer tissue was analysed by staining of a human tissue microarray (TMA). Functional
effects of Cdk5 overexpression, genetic knockdown by siRNA and shRNA, and pharmacologic inhibition by the small molecule
roscovitine were tested in migration, invasion, cell death, and tumorsphere assays and in tumour establishment in vivo. For
mechanistic studies, molecular biology methods were applied.
Results: In fact, here we pin down a novel function of Cdk5 in TICs: knockdown and pharmacological inhibition of Cdk5 impaired
tumorsphere formation and reduced tumour establishment in vivo. Conversely, Cdk5 overexpression promoted tumorsphere
formation which was in line with increased expression of Cdk5 in human breast cancer tissues as shown by staining of a human
TMA. In order to understand how Cdk5 inhibition affects tumorsphere formation, we identify a role of Cdk5 in detachment-
induced cell death: Cdk5 inhibition induced apoptosis in tumorspheres by stabilizing the transcription factor Foxo1 which results
in increased levels of the pro-apoptotic protein Bim.
Conclusions: In summary, our study elucidates a Cdk5-Foxo1-Bim pathway in cell death in tumorspheres and suggests Cdk5 as a
potential target to address TICs.
Tumour-initiating cells (TICs) limit therapeutic success of anti-
cancer chemotherapy as they show high tumour-initiating
potential, cause the establishment of metastases and are resistant
to standard therapy (Mani et al, 2008; Scheel and Weinberg, 2012;
Pinto et al, 2013; Pattabiraman and Weinberg, 2014). Conse-
quently, therapeutic strategies that address TICs may substantially
improve anti-cancer treatment and patient prognosis.
In order to find new approaches for targeting TICs, research on
TICs has been strongly intensified during recent years. Various
mechanisms that contribute to TIC generation and survival have
been elucidated (Scheel and Weinberg, 2012); TIC generation has
been associated with epithelial–mesenchymal transition (EMT), a
process of cellular plasticity that confers mesenchymal properties
to epithelial cells. During EMT, epithelial cells change their
morphology, acquire highly migratory and invasive mesenchymal
traits and gain stem-like properties (Mani et al, 2008; Scheel et al,
2011; Schmidt et al, 2015). Mechanisms responsible for the
increased survival of TICs include increased DNA damage repair,
altered cell cycle checkpoint control, overexpression of drug efflux
proteins like multidrug resistance transporters as well as impaired
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apoptosis (Signore et al, 2013). Nevertheless, our understanding of
the mechanisms and the regulation of signalling components
contributing to TIC survival is still limited.
Cdk5 is a serine/threonine kinase pivotal for neuronal develop-
ment, synaptic plasticity and neurotransmission and implicated in
neurodegenerative diseases like Alzheimer’s and Parkinson’s disease
(Dhavan and Tsai, 2001). During the last years, important non-
neuronal functions of Cdk5 have been elucidated (Liebl et al, 2011a).
Amongst others, our own studies demonstrated indispensable
functions of endothelial Cdk5 in lymphatic vessel development
(Liebl et al, 2015) and in tumour angiogenesis (Merk et al, 2016).
Moreover, recent studies elucidated functions of Cdk5 in cancer, for
example, we elucidated a role of Cdk5 in DNA damage response in
hepatocellular carcinoma (HCC; Ehrlich et al, 2015). Importantly,
Cdk5 was associated with tumour initiation: aberrant Cdk5 activity
induced neuroendocrine medullary thyroid carcinoma (Pozo et al,
2013) and ASCL1-driven upregulation of Cdk5 contributed to the
establishment of neuroendocrine and small-cell cancers (Meder et al,
2016). Notably, Cdk5 has recently been linked with EMT (Liang et al,
2013; Ren et al, 2015; Sun et al, 2015). However, a function of Cdk5 in
TICs has not been described yet.
Along this line, we hypothesised that Cdk5 might contribute to
tumour initiation. According, the aim of the present study was to
evaluate a potential role and the molecular signalling of Cdk5 in
TICs in order to judge Cdk5 as a potential target to address TICs.
MATERIALS AND METHODS
Cells. Cells were cultured under constant humidity at 37 1C and
5% CO2. MCF10A cells were from ATCC (Manassas, VA, USA)
and cultured with DMEM/Ham’s F12 containing Horse serum 5%,
EGF 20 ngml 1, Insulin 5 mgml 1, Hydrocortisone 0.5mgml 1,
Choleratoxin 0.1 mgml 1 and penicillin/streptomycin (P/S).
MCF7 cells were from DSMZ (Braunschweig, Germany) and
cultured with RPMI 1640 containing FCS 10%, Insulin 5mgml 1,
Pyruvate 1mM, NEAA 1% and P/S. The human urinary carcinoma
cell line T24 was kindly provided by Dr B Mayer (Surgical
Clinic, LMU, Munich, Germany). T24 were cultured with
McCoys´ medium containing FCS 10%, glutamine (1.5mM) and
for lentiviral-transduced T24 cells, puromycin (1mgml 1) was
used. Immortalised human mammary epithelial (HMLE) cells
stably transfected with Twist-ER were described previously (Scheel
et al, 2011). In brief, HMLE cells were cultivated in mammary
epithelial cell growth medium (PromoCell GmbH, Heidelberg,
Germany) supplemented with P/S (PAA Laboratories, Pasching,
Austria) and 10mgml 1 blasticidin (Gibco, Germering, Germany).
To induce EMT, HMLE Twist-ER cells were treated with 20 nM
4-Hydroxytamoxifen (4-OH-TX; Sigma-Aldrich, Taufkirchen,
Germany) for 10 days, whereby cells were split and supplied with
fresh medium and stimulation reagents every 3 days.
Transfection of cells. Overexpression experiments were per-
formed using FuGENE HD reagent (Promega, Madison, WI,
USA) according to the manufacturers protocol with a reagent:DNA
ratio of 3 : 1. The following plasmids were used: Cdk5 (addgene
1871), p35 (addgene 1347).
Silencing experiments were performed with DharmaFECT 1
Transfection Reagent (Thermo Scientific, Waltham, MA, USA)
corresponding to the manufacturers recommendation. The follow-
ing siRNAs were used: non-targeting (nt) siRNA: D-001810-01;
Cdk5 siRNA: J-003239-09 and J-003239-10 (Thermo Scientific/
Dharmacon, Lafayette, CO, USA).
For stable downregulation of Cdk5, lentiviral transduction
with non-targeting (nt) and Cdk5 shRNA was performed using
MISSION shRNA Lentiviral Transduction Particles (Sigma-
Aldrich) according to the manufacturer’s protocol.
Cell viability assay. Cells were seeded in 96-well plates and
incubated for 24 h. Cells were treated as indicated for further 24 h.
Cell viability was measured using CellTiter-Blue reagent (Promega)
according to the manufacturers protocol.
Proliferation assay. Cells were seeded in 96-well plates and
incubated for 24 h. The initial cell number was determined. Cells
were treated as indicated for further 72 h. Cell viability was
measured using CellTiter-Blue reagent (Promega) according to the
manufacturers protocol. For proliferation assay cells were stained
with crystal violet (0.5% in methanol 20%), lysed with sodium
citrate (0.05M in ethanol 50%) and absorbance (550 nm) was
measured in a plate-reading photometer (SpectraFluor PlusTM,
Tecan, Crailsheim, Germany).
Apoptosis analysis. Apoptosis was performed according to
Nicoletti et al (1991). Briefly, tumorspheres were collected, washed
and stained with HFS-solution containing PI (50 mgml 1,
overnight, 4 1C) followed by flow cytometry (FACSCantoII, BD
Biosciences, Franklin Lakes, NJ, USA) the next day. SubG1 cells
were analysed using the FlowJo 7.6 analysis software (Tree Star
Inc., Ashland, OR, USA). Percentage of specific apoptosis was
calculated using the formula 100 ((experimental apoptosis (%)
spontaneous apoptosis (%))/(100% spontaneous apoptosis (%));
Fulda et al, 2001).
Clonogenic growth. Cells were treated as indicated for 24 h.
Afterwards, cells were trypsinized and freshly seeded (5000 cells
per 6-well) and incubated for 7 days. Colonies were stained
with crystal violet (0.5% in methanol 20%), lysed with sodium
citrate (0.05M in ethanol 50%) and the absorbance was measured
in a plate-reading photometer (SpectraFluor PlusTM, Tecan,
Crailsheim, Germany).
Migration and invasion. After indicated treatments (24 h), cells
were labelled with CellTrackerGreen CMFDA (Life Technologies,
Carlsbad, CA, USA), resuspended in medium without serum and
added to the upper compartment of the transwell chamber
(6.5mm, polycarbonate membrane, 8.0 mm pore size, Corning
Incorporated, Tewksbury, MA, USA). For invasion assays, the
transwell inserts were coated with Matrigel. Culture medium
containing 10% serum was added to the lower chamber, medium
without serum served as negative control. After migration, cells
were fixed in 4% PFA (10min) and cells in the upper chamber
were removed using cotton buds. Four pictures per well were taken
by means of an inverted microscope (Axiovert 25/200, Zeiss, Jena,
Germany) at 10-fold magnification. Cells were counted using
ImageJ software.
Sphere formation assay. Sphere formation assays were performed
as described (Dontu et al, 2003). Cells were treated with
Roscovitine (24 h) or transfected as indicated (48 h). Cells were
resuspended in sphere-formation medium containing 1% methyl
cellulose (Sigma-Aldrich) and seeded into poly-(2-hydroxyethyl
methacrylate; pHEMA, Sigma-Aldrich)-coated 12-well plates at
4 104 cells per well. After incubation for 10 days, 12 pictures per
well were taken by using a LSM 510 Meta (Zeiss, Jena, Germany)
microscope. Number of spheres bigger than 50 mm was evaluated
using ImageJ.
Immunoblotting. Immunoblotting was performed as described
(Ehrlich et al, 2015). The following primary antibodies were used:
AKT (9272, Cell Signaling), AKT phospho (Ser 473; 4051, Cell
Signaling), b-actin (MAB1501, Millipore), b-tubulin (2146, Cell
Signaling), Bim (2819, Cell Signaling), Cdk5 (AHZ0492, Life
Technologies), COX IV (4844, Cell Signaling), CREB (9104, Cell
Signaling), ERK (9102, Cell Signaling), ERK phospho (9106, Cell
Signaling), Foxo1 (2880, Cell Signaling), GAPDH (sc-69778,
Santa Cruz), HIF1a (610958, BD Biosciences), phospho-histone
H2aX (gH2aX, 2577, Cell Signaling), matrix metalloproteinase-9
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(MMP-9; 3852 Cell Signaling), MMP-2 (4022 Cell Signaling),
NICD-1 (4147, Cell Signaling), NICD-4 (sc-5594, Santa Cruz),
Notch 1 (3608, Cell Signaling), Retinoblastoma protein phospho
(Ser807/811; 8516, Cell Signaling), Retinoblastoma protein
(554136, BD Biosciences), Stat3 phospho (Ser 727; 9134, Cell
Signaling), Stat3 (9132, Cell Signaling). Anti-vimentin, -snail, -b-
catenin, -claudin-1, N-cadherin were from Cell Signaling (EMT
Sampler Kit, 9782), c-Myc (sc-788, Santa Cruz). Loading control by
stain-free gels was performed by adding 0.5% TCE (2,2,2-
Trichloroethanol, Sigma-Aldrich) to the PAGE gels according to
the TGX Stain-Free Gels system (BioRad, Hercules, CA, USA).
Kinase activity assay. Cdk5 was immunoprecipitated using anti-
Cdk5 antibody (sc-173, Santa Cruz Biotechnology) and Protein G
Agarose beads (Sigma-Aldrich). Beads were resuspended in 50ml
kinase buffer (50mM HEPES pH 7.0, 10mM MgCl2, 1mM DTT, 1mM
NaF, 1mM Na3VO4, 1mM PMSF, 3mM b-glycerophosphate, 4mM
Complete EDTAfree). An aliquot of 2mM ATP, 10mCi 32P-g-ATP
(Hartmann Analytic, Braunschweig, Germany) and 0.05mgml 1
histone H1 (Type III from calf thymus, Sigma-Aldrich) were added
and samples were incubated at 30 1C for 20min before termination by
boiling with 5 SDS sample buffer (5min, 95 1C). Electrophoresis
and autoradiography was performed.
Immunostaining. Cells were seeded in 8-well slides (ibidi GmbH,
m-Slide 8-Well ibiTreat, 80826), washed, fixed with 4% PFA and
permeabilized using 0.1% TritonX-100. After blocking, cells were
incubated with anti-Foxo1 antibody and a secondary antibody
(Alexa Fluor 488, A-11008, Invitrogen (Carlsbad, CA, USA); 1 h
each). Nuclei were visualised using 5mgml 1 Hoechst33342.
Microscopy was conducted using LSM 510 Meta (Zeiss, Jena,
Germany) microscope.
Mitochondrial fractionation. Cells were collected, incubated with
permeabilization buffer for 20min on ice (210mM mannitol,
200mM sucrose, 10mM HEPES, pH 7.2, 0.2mM Na2EGTA, 5mM
succinate, bovine serum albumin 0.15%, 80 mgml 1 digitonin) and
centrifuged (1300 r.p.m., 4 1C, 10min). The supernatant was
collected (cytosolic fraction) and the pellet permeabilized with
0.1% TritonX-100 (15min, on ice; mitochondrial fraction).
Cytosol-nuclei fractionation. Cells were collected, washed and
pelleted (1500 r.p.m., 4 1C, 5min). The pellet was incubated with
BufferA (10mM HEPES, pH 7.9, 10mM KCl, 0.1mM EDTA, 0.1mM
EGTA, 1mM DTT, 0,5mM PMSF, Complete 1 : 100) for 15min.
After addition of Nonidet P-40 10% cells were again pelleted
(12 000 r.p.m., 4 1C, 1min). The supernatant (cytosolic fraction)
was removed and the pellet was resuspended in hypertonic BufferB
(20mM HEPES, pH 7.9, 0,4mM NaCl, 1mM EDTA, 1mM EGTA,
25% Glycerol, 1mM DTT, 1mM PMSF, Complete 1 : 100; 15min,
4 1C shaker). After centrifugation (12 000 r.p.m., 4 1C, 5min) the
supernatant was taken as nuclei fraction.
Quantitative real-time PCR. Cells were collected and RNA was
isolated using RNeasy Mini Kit (74106, Qiagen, Hilden, Germany)
according to the manufacturers protocol. Reverse transcription was
conducted using High Capacity cDNA Reverse Transcription Kit
(4368814, Life technologies). Bim primers were purchased from
Life technologies (4453320). E-cadherin, N-cadherin and vimentin
primers were purchased from Metabion international AG.
(E-Cadherin fw 50 CAG CAC GTA CAC AGC CCT AA 30, rv 50
AAG ATA CCG GGG GAC ACT CA 30; N-Cadherin fw 50 ACA
GTG GCC ACC TAC AAA GG 30, rv 50 CCG AGA TGG GGT
TGA TAA TG 30; Vimentin fw 50 CGG CGG GAC AGC AGG 30,
rv 50 TCG TTG GTT AGC TGG TCC AC 30). GAPDH was used as
control.
CD44 staining and FACS analysis. For CD44 surface protein
quantification, a FITC labelled CD44 antibody was used (560977,
BD Pharmingen). CD44 staining was carried out according to the
manufacturers protocol. FITC Mouse IgG2b k antibody was used
as isotype control (555742, BD Pharmingen). Surface expression
was measured by a flow cytometer (FACS Canto, BD Pharmingen).
For gating and population analysis FlowJo 7.6 software (Tree Star
Unc.) was used.
Tumour xenograft model. Mouse experiments were performed
with approval by the District Government of Upper Bavaria in
accordance with the German animal welfare and institutional
guidelines. T24 cells stably transfected with non-targeting shRNA
and Cdk5 shRNA (1 105 cells in 100 ml PBS) were subcuta-
neously injected into the flanks of 6-week-old female Balb/c nude
mice (Harlan Envigo). Five mice per group were used. The time of
tumour establishment and the number of established tumours was
determined.
Immunohistochemistry. For staining of tumour sections,
tumours were removed, fixed with PFA 4% for 24 h, left in PFA
1%, embedded into paraffin and 10 mm sections were prepared.
The slides were deparaffinized in xylene (15min) and rehydrated
through descending concentrations of ethanol (20min in 100%
and 20min in 95%). For antigen retrieval sections were boiled in
sodium citrate buffer (10mM sodium citrate, 0.05% Tween 20, pH
6.0) for 20min. Endogenous peroxidase was blocked by incubation
in 7.5% hydrogen peroxide for 10min. For staining of the human
tissue microarray (TMA), anti-Cdk5 antibody (Thermo Fisher
Scientific, AHZ0492), diluted 1 : 100 in PBS, was applied as
primary antibodies for 1 h at room temperature. For antibody
detection Vectastain Universal Elite ABC Kit (Vector Laboratories,
Burlingame, CA, USA) was taken according to the manual and
AEC (Vector Laboratories) was used as a chromogen. Slides were
counterstained with hematoxylin for 1min and mounted using
FluorSave Reagent mounting medium (Merck, Darmstadt,
Germany). Images were obtained with an Olympus BX41
microscope and an Olympus DP25 camera (Olympus, Tokyo,
Japan). Cdk5 staining of the TMA section was assessed using the
(Remmele and Stegner, 1987) immunoreactive score as described 0
absent; 1–4 weak; 5–8 moderate; 9–12 strong expression.
Statistical analysis. All experiments were performed at least three
times unless otherwise indicated in the figure legend. Data are
expressed as mean±s.e.m. Statistical analysis was performed with
GraphPad Prism (version 5.04, GraphPad Software, Inc., La Jolla,
CA, USA). Statistical significance was assumed if Pp0.05.
RESULTS
Expression of Cdk5 in human cancer tissue. Analysis of Cdk5
expression revealed increased levels of Cdk5 in the cancer cell lines
MCF7 and T24, and MDA-MB-231 in comparison to the non-
cancerous epithelial cell line MCF10A (Figure 1A). This was in line
with the expression of Cdk5 in human cancer tissue: staining of a
human TMA from 198 female breast cancer patients revealed that
Cdk5 expression seemed to be stronger in cancer tissue compared
to healthy breast tissue. The staining was evaluated according to
the IRS score showing that human tumour tissues expressed Cdk5
in 22.5% at low IRS score, in 46.1% at medium IRS score and in
31.4% at high-IRS score, whereas healthy tissues expressed Cdk5
only at low (28.6%) or median (71.4%) intensity (Figure 1B).
A strong staining-intensity was not detected in healthy breast
tissue. Moreover, Cdk5 expression and kinase activity (Histone H1
phosphorylation) were increased in cells with an EMT-induced
mesenchymal phenotype in comparison to epithelial cells
(Figure 1C and D). This set of data points to a role of Cdk5 in
mesenchymal tumour cells.
Cdk5 regulates growth and motility of cancer cells. Next, the
impact of genetic knockdown of Cdk5 with transient silencing by
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siRNA and stable lentiviral shRNA transduction as well as
pharmacological inhibition of Cdk5 with the small molecule
roscovitine on cancer cell functions was analysed. Cdk5 inhibition
impaired cancer cell growth as the proliferation of Cdk5 shRNA
cells was reduced (Figure 2A). In line, pharmacological inhibition
of Cdk5 with roscovitine concentration dependently reduced
proliferation and cell viability of various breast and bladder cancer
cell lines (Figure 2B and C). Although Cdk5 expression and kinase
activity was increased in cells with a mesenchymal phenotype,
EC50 of roscovitine was similar in epithelial (MCF10A, MCF7,
T24), as well as in mesenchymal (MDA-MB-231, EMT-induced
HMLE) cell lines. This might be due to the expression of different
Cdks by the cell lines which are inhibited by roscovitine and
therefore contribute to its anti-proliferative effect. Moreover, both
Cdk5 downregulation and inhibition reduced long-term colony
formation (Figure 2D and E).
Besides abrogating cancer cell growth, Cdk5 knockdown
reduced cancer cell migration and invasion (Figure 3A and B
Supplementary Figure 1). A concentration-dependent decrease of
migration by Cdk5 inhibition with roscovitine again demonstrates
pharmacologic accessibility of Cdk5 (Figure 3C).
Cdk5 regulates sphere formation. To analyse a potential function of
Cdk5 in cancer stem cell (TIC) formation, we performed tumorsphere
assays with cultivation of cells under specific conditions in suspension
and with serum starvation which exclusively allows clonal expansion
of TICs. In fact, Cdk5 knockdown with shRNA (Figure 4A) as well as
inhibition with roscovitine (Figure 4B and C and Supplementary
Figure 2) reduced tumorsphere formation. Conversely, Cdk5 over-
expression in non-cancerous epithelial cells led to increased sphere
formation (Figure 4D). Furthermore, time of establishment and
number of established tumours was reduced by Cdk5 knockdown
in vivo (Figure 4E). In sum, this set of data suggests a potential
contribution of Cdk5 to tumour initiation.
Cdk5 does not regulate tumorsphere formation by modulating
EMT and cell survival. To understand how Cdk5 contributes to
tumorsphere formation, we first focused on EMT as Cdk5 was
recently described to contribute to TGFb-induced EMT (Liang et al,
2013) and as our data showed that Cdk5 was activated in cells that
have undergone EMT (Figure 1C and D). However, common EMT
markers like the epithelial marker E-cadherin and the mesenchymal
markers N-cadherin and vimentin were not changed by Cdk5
knockdown (Figure 5A and B). The generation of TICs as well as the
EMT process itself are described to be influenced by Notch signalling
pathways (Harrison et al, 2010a) and we recently elucidated that Cdk5
interferes with Notch signalling in tumour angiogenesis (Merk et al,
2016). Nevertheless, Cdk5 neither influenced the generation of active
Notch1 and Notch4 intracellular domains N1-ICD and N4-ICD nor
the Notch downstream target c-Myc that have been associated with
TICs (Cho et al, 2010; Harrison et al, 2010b; Lombardo et al, 2012;
Figure 5C). Moreover, the expression of CD44, a transmembrane
adhesion receptor that directs the migration of mesenchymal stem
cells and represents a characteristic surface molecule of TICs (Zoller,
2011) was not changed in Cdk5 knockdown cells (Figure 5D). Finally,
keeping in mind that Cdk5 affects cell migration and invasion we
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Figure 1. Expression of Cdk5 in human cell lines and cancer tissue. (A) The immunoblots show levels of Cdk5 in breast epithelial cells MCF10A,
and cancer cell lines MDA-MB-231, MCF7 and T24. Actin indicates equal loading (n¼ 3). (B) Representative immunostainings from a human breast
cancer TMA show Cdk5 expression in healthy mamma tissue and breast cancer tissues. The table displays the evaluation of Cdk5 expression in
tumour tissues (n¼198) and healthy tissues (controls, n¼ 7) according to the IRS score (intensitypositivity). (C) Immunoblots show Cdk5
expression in HMLE cells that have (þ ) or have not ( ) undergone EMT. Tubulin indicates equal loading (n¼ 3). (D) Cdk5 activity in HMLE cells
that have (þ ) or have not ( ) undergone EMT is shown by phosphorylated histone H1 (p-H1; n¼3).
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Figure 2. Cdk5 inhibition impairs cancer cell growth. (A) Proliferation of non-targeting (nt) or Cdk5 shRNA-transduced cells is shown
(mean±s.e.m., *Po0.001, n¼3). Immunoblots of non-targeting (nt) or Cdk5 shRNA-transduced T24 cells for Cdk5 and b-actin (loading control)
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further focused on MMPs which were also described to drive cancer
progression via the EMT process (Radisky and Radisky, 2010).
However, MMP2 and MMP9 were not influenced by Cdk5
(Figure 5E). This set of data suggests that the observed impact of
Cdk5 on sphere formation is not due to a regulation of the EMT
process. Next, we investigated whether pathways that have been
associated with cancer cell survival are influenced by Cdk5. AKT,
ERK, Hypoxia-inducible factor HIF1a or Stat3 can contribute to
detachment-induced survival (Lin et al, 2007; Courapied et al,
2010; Hsu et al, 2013; Buchheit et al, 2014; Hu et al, 2015b),
but were not modulated by Cdk5 knockdown in tumorspheres
(Figure 5F). Additionally, the phosphorylation of Retinoblastoma
protein (Rb), a cell cycle regulator and target of Cdk5 in neuro-
endocrine thyroid cancer (Pozo et al, 2013) was not affected by
Cdk5 knockdown (Figure 5F). We previously elucidated that Cdk5
regulates DNA damage response in HCC (Ehrlich et al, 2015).
However, phosphorylation of histone H2aX which is caused by DNA
damage was not modulated by Cdk5 knockdown in T24 cells
(Figure 5G).
Cdk5 inhibition mediates cell death in tumorspheres by increasing
the pro-apoptotic protein Bim. TICs are often resistant to
apoptotic cell death by altering proteins of the apoptosis machinery
(Keitel et al, 2014). In fact, cell death was increased in tumorspheres
from Cdk5 knockdown cells (Figure 6A) or in cells with pharm-
acologic Cdk5 inhibition (Figure 6B, Supplementary Figure 3). In
addition, the pro-apoptotic BH3-only protein Bim that is a known
mediator of detachment-induced cell death (Maamer-Azzabi et al,
2013; Buchheit et al, 2015) was increased in Cdk5 knockdown cells
(Figure 6C). As the intrinsic apoptosis machinery is activated by Bim
translocation to mitochondria (Buchheit et al, 2015), we performed
mitochondria fractionation at different time points of cell detach-
ment which revealed that Bim protein was increased in mitochondria
from Cdk5 knockdown cells (Figure 6D). By investigating how Cdk5
knockdown affects Bim, we observed an increase in Bim mRNA in
Cdk5 knockdown cells (Figure 6E). The transcription of Bim is
regulated by forkhead transcription factor type O (Foxo) proteins
and Cdk5 has previously been linked with Foxo1 in neurons (Zhou
et al, 2015). In fact, we observed that Cdk5 knockdown and
inhibition increased Foxo1 (Figure 6F and G) both in the cytoplasm
as well as in the nucleus (Figure 6H and I), whereas mRNA
transcription was not affected (Supplementary Figure 4). In sum, this
set of data suggests that Cdk5 regulates cell death in tumorspheres by
mediating Bim transcription via Foxo1.
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DISCUSSION
Tumor-initiating cells represent a major problem in cancer therapy as
they account for tumour recurrence, establishment of metastasis and
resistance towards therapeutics. Thus, recent research strongly
focused on investigating TIC properties and mechanisms that are
involved in TIC formation and maintenance in order to drive the
development of anti-TIC therapies (Pattabiraman and Weinberg,
2014): Signalling pathways which contribute to the self-renewing
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properties of stem cells like TGFb, WNT, Notch and Hedgehog are
supposed as potential attractive targets to address TICs. In fact,
various compounds addressing components of these pathways have
shown anti-TIC effects and are currently investigated in clinical trials.
In order to identify targeted therapies that address TICs, compound
library screens have been carried out and, amongst others, identified
the compound salinomycine as anti-TIC drug. Moreover, anti-TIC
approaches include targeting of the tumour microenvironment which
often triggers EMT induction and tumour initiation. Differentiation
therapy by all-trans retinoic acid promotes the differentiation of
promyelocytic leukaemic cells into mature granulocytes and is
successfully used in therapy of promyelocytic leukaemia. Likewise,
also other forms of cancers associated with TICs might be effectively
treated by differentiation inducing therapeutics. In addition, immu-
notherapy and the targeting of TIC metabolism were supposed as
promising potential anti-TIC strategies. All in all, there are some
promising drugs and strategies, but there is still a craving need for
more candidates to address TICs.
In fact, here, we elucidate Cdk5 as a novel player in TICs which
might point to Cdk5 as a potential target to address TICs. Cdk5 can be
addressed pharmacologically and Cdk-inhibiting small molecules are
currently investigated as potential anti-cancer drugs (Liebl et al, 2011b;
Weitensteiner et al, 2013; Ehrlich et al, 2015). Two Cdk inhibitors are
currently evaluated in clinical trials: Roscovitine represents a well-
established inhibitor of Cdks that has been developed in the late 1990
(Meijer et al, 1997). It has shown modest anti-cancer activity in
xenograft tumour models in vivo and has been tested in a number of
Phase I and II clinical trials where it has shown some anti-cancer
activity in around half of the patients (Khalil et al, 2015). Dinaciclib, a
newer Cdk inhibitor, has demonstrated significant clinical activity in
patients with lymphocytic leukaemia and multiple myeloma (Flynn
et al, 2015; Kumar et al, 2015). Moreover, dinaciclib in combination
with an AKT-inhibitor showed therapeutic efficiency in patient-derived
human pancreatic cancer xenograft models and will be followed by
clinical trial evaluation (Hu et al, 2015a). These results are very
promising, however, in contrast, a phase I trial with patients suffering
from triple-negative breast cancer has demonstrated severe toxic effects
and failure of treatment response of a combination treatment of
dinaciclib and epirubicin (Mitri et al, 2015). Thus, further trials are
required to evaluate the potential of dinaciclib as anti-cancer agents.
In order to investigate the underlying mechanism of Cdk5 in TICs,
we first focused on EMT as recent studies demonstrated an
involvement of Cdk5 in EMT (Liang et al, 2013; Ren et al, 2015;
Sun et al, 2015). Moreover, the forkhead transcription factor Foxc2
was identified as a critical regulator of EMT and TICs in breast cancer
(Hollier et al, 2013) and we recently elucidated a relationship between
Cdk5 and Foxc2 in the lymphatic endothelium (Liebl et al, 2015). In
line, our results revealed that Cdk5 expression was increased in cells
that have undergone EMT and in human cancer tissues. Nevertheless,
Cdk5 did not regulate tumorsphere formation by EMT, suggesting a
specific function of Cdk5 in TICs. Recently, Cdk5 was shown to
contribute to the initiation of small-cell lung cancer: overexpression of
the NOTCH target ASCL1-induced activation of Cdk5 that
phosphorylated and inactivated Rb1 (Meder et al, 2016). In line,
aberrant Cdk5 activity was shown to promote tumorigenesis of
medullary thyroid cancer by phosphorylation of the retinoblastoma
protein (Rb1; Pozo et al, 2013). Nevertheless, Cdk5 did not modulate
Notch or Rb1 in Cdk5 knockdown cells. In fact, our work proposed a
role of Cdk5 in cell death of tumorspheres by regulating the pro-
apoptotic protein Bim. This is in line with previous studies showing
that pro-apoptotic proteins like Bim were diminished in cells that
have undergone EMT which contributed to apoptosis resistance of
TICs (Keitel et al, 2014). As Bim suppressed the survival of
disseminated tumour cells (Merino et al, 2015) and induced apoptosis
in leukaemia stem/progenitor cells (Pan et al, 2015), induction of Bim
might represent a potential anti-TIC strategy. As mechanism of Cdk5
to control Bim, we found that Cdk5 knockdown increased Bim at the
transcriptional level by increasing the Forkhead box Type O
transcription factor 1 (Foxo1). This is in line with findings in
neurons, as neuronal Cdk5 regulates Foxo1 by phosphorylation at its
S249 site, favoring its nuclear export and inhibiting its transcriptional
activity (Zhou et al, 2015). Foxos play a pivotal role in tumour
suppression and are regulated by PI3K/AKT; nuclear Foxos induce
the expression of pro-apoptotic genes such as Bim, leading to cell
death, whereas AKT-mediated phosphorylation induces cytoplasmic
translocation and inhibits Foxo target gene transcription (Calnan and
Brunet, 2008). In line with our study, the Akt/Foxo3/Bim pathway has
been previously shown to be associated with cancer stem cell survival
(Gargini et al, 2015).
In summary, our results demonstrate a Cdk5-Foxo1-Bim pathway
in cell death in tumorspheres. As Cdk5 is pharmacologically
accessible, it is suggested as a potential target to address TICs.
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Supplementary Figure 1. Cdk5 inhibition reduces cancer cell motility. (A) FCS-induced migration of non-targeting(nt) or Cdk5 siRNA treated MCF7 cells is shown (mean ± SEM, *p<0.001, n=3). Immunoblots of non-targeting (nt) orCdk5 siRNA treated MCF7 cells for Cdk5 and β-actin (loading control) proof Cdk5 knockdown. (B) FCS-inducedmigration of non-targeting (nt) or Cdk5 siRNA treated T24 cells is shown (mean ± SEM, *p<0.001, n=3). Immunoblotsof non-targeting (nt) or Cdk5 siRNA treated T24 cells for Cdk5 and β-actin (loading control) proof Cdk5 knockdown.(C) FCS-induced invasion of T24 cells treated with non-targeting (nt) or Cdk5 siRNA is shown (mean ± SEM, *p<0.001,n=3).
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Supplementary Figure 2
Supplementary Figure 2. Cdk5 regulates tumorsphere formation. (A) Tumorsphere formation after pretreatment ofcells with roscovitine for 24 h before resuspension in fresh sphere-formation medium and cultivation for further 10days is shown (mean ± SEM, *p<0.001, n=3). (B) Tumorsphere formation after pretreatment of mesenchymal HMLEcells with roscovitine for 24 h before resuspension in fresh sphere-formation medium and cultivation for further 10days in presence of roscovitine is shown (mean ± SEM, n=3). (C) Tumorsphere formation after pretreatment of MDA-MB-231 cells with roscovitine for 24 h before resuspension in fresh sphere-formation medium and cultivation forfurther 10 days in presence of roscovitine is shown (mean ± SEM, n=3).
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Supplementary Figure 3. Cdk5 induces apoptosis of tumorspheres. (A) Specific apoptosis of MDA-MB-231tumorspheres after pretreatment of cells with roscovitine for 24 h before resuspension in fresh sphere-formationmedium and cultivation for further 10 days in presence of roscovitine is shown (mean ± SEM, n=3). (B) Specificapoptosis of tumorspheres from mesenchymal HMLE cells (HMLEmes) after pretreatment of cells with roscovitine for24 h before resuspension in fresh sphere-formation medium and cultivation for further 10 days in presence ofroscovitine is shown (mean ± SEM, *p<0.05, n=3).
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Supplementary Figure 4
Supplementary Figure 4. Cdk5 does not regulate Foxo1 at mRNA level. Foxo1 mRNA of non-targeting (nt) and Cdk5shRNA cells is shown (mean ± SEM, n.s. = not significant, n=3).
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